Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Evaluation of ACUVUE OASYS® 1 -Day for Astigmatism Lenses Produced on a New 
Manufacturing Line
Protocol CR-6420
Version: 1.0
Date: 05November 2020
Investigational Products: ACUVUE OASYS® 1-Day for Astigmatism
Keywords: Astigmatism, ACUVUE OASYS® 1 -Day for Astigmatism, senofilcon A, daily 
wear, daily disposable, dispensing, Single use Eye -Cept® Rewetting Drops, LacriPure Saline 
Solution, ScleralFil Preservative  Free Saline Solution, CLUE comfort, CLUE vision, CLUE 
handling, logMAR visual ac uity, rotation performance.
Statement of Compliance to protocol, GC P and applicable regulatory guidelines:
This trial will be conducted in compliance with the proto col, ISO 14155 ,1the International 
Council for Harmonization Good Clinical Practice E6 (R2) (ICH GCP) ,2the Declaration of 
Helsinki ,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confident ial information, which should not be copied, referred to, 
released or published without written approval from Johnson & Johnson Vision Care, Inc. The 
information may not be disclosed to others exce pt to the extent necessary to obtain Institutional 
Review Board/Independent Ethics Committee a pproval and informed consent, or as required 
by International, Federal and State Laws, as a pplicable. Persons to whom this information is 
disclosed must be inform ed that this information is privile ged and confidential and that it 
should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential a nd proprietary to Johnson & Johnson Vision Ca re, Inc. and must be kept in 
confidence in the same manner as the contents of this document.
CR-6420, v1.0
Page 1 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE ................................ ...................... 6 
SPONSOR NAME AND ADDRESS ................................ ................................ ....................... 6 
MEDICAL MONITOR ................................ ................................ ................................ ............. 6 
AUTHORIZED SIGNATURES ................................ ................................ ............................... 7 
CHANGE HISTORY ................................ ................................ ................................ ................ 8 
SYNOPSIS ................................ ................................ ................................ ................................ 9 
COMMONLY USED ABBREVIATION S, ACRONYMS AND DEFINITIONS OF TERMS
................................ ................................ ................................ ................................ ................. 15 
1. INTRODUCTION AND BACKGROUND ................................ ................................ ...16 
1.1. Name and Descriptions of Investigational Products ................................ ................ 16 
1.2. Intended Use of Investigational Products ................................ ................................ .16 
1.3. Summary of Findings from Nonclinical Studies ................................ ...................... 16 
1.4. Summary of Known Risks and Benefits to Human Subjects ................................ ...16 
1.5. Relevant Literature References and Prior Cl inical Data Relevant to Proposed Clinical 
Study ……………………………………………………………………………………... 17 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ................................ ......17 
2.1. Objectives ................................ ................................ ................................ ................. 17 
2.2. Endpoints ................................ ................................ ................................ .................. 17 
2.3. Hypotheses ................................ ................................ ................................ ............... 17 
3. TARGETED STUDY POPULATION ................................ ................................ ........... 17 
3.1. General Characteristics ................................ ................................ ............................ 17 
3.2. Inclusion Criteria ................................ ................................ ................................ ......17 
3.3. Exclu sion Criteria ................................ ................................ ................................ .....18 
3.4. Enrollment Strategy ................................ ................................ ................................ ..19 
4. STUDY DESIGN AND RATIONALE ................................ ................................ .......... 19 
4.1. Description of Study Design ................................ ................................ .................... 19 
4.2. Study Design Rationale ................................ ................................ ............................ 19 
4.3. Enrollment Target and Study Duration ................................ ................................ ....20 
5. TEST ARTICLE ALLOCATION AND MASKING ................................ ..................... 20 
5.1. Test Article Allocation ................................ ................................ ............................. 20 
5.2. Masking ................................ ................................ ................................ .................... 21 
5.3. Procedures for Maintaining and Breaking the Masking ................................ ........... 21 
6. STUDY INTERVENTION ................................ ................................ ............................. 21 
CR-6420, v1.0
Page 2 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.1. Identity of Test Articles ................................ ................................ ............................ 21 
6.2. Ancillary Supplies/Products ................................ ................................ ..................... 23 
6.3. Administration of Test Articles ................................ ................................ ................ 23 
6.4. Packaging and Labeling ................................ ................................ ........................... 23 
6.5. Storage Conditions ................................ ................................ ................................ ...24 
6.6. Collection and Storage of Samples ................................ ................................ .......... 24 
6.7. Accountability of Test Articles ................................ ................................ ................ 24 
7. STUDY EVALUATIONS ................................ ................................ .............................. 25 
7.1. Time an d Event Schedule ................................ ................................ ......................... 25 
7.2. Detailed Study Procedures ................................ ................................ ....................... 26 
VISIT 1 ................................ ................................ ................................ ........................... 26 
VISIT 2 ................................ ................................ ................................ ........................... 33 
VISIT 3 ................................ ................................ ................................ ........................... 35 
VISIT 4 ................................ ................................ ................................ ........................... 36 
FINAL EVALUATION ................................ ................................ ................................ ..37 
7.3. Unscheduled Visits ................................ ................................ ................................ ...38 
7.4. Labor atory Procedures ................................ ................................ ............................. 39 
8. SUBJECTS COMPLETION/WITHDRAWAL ................................ .............................. 40 
8.1. Completion Criteria ................................ ................................ ................................ ..40 
8.2. Withdrawal/Discontinuation from the Study ................................ ........................... 40 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 41 
9.1. Systemic Medications ................................ ................................ .............................. 41 
10. DEVIATIONS FROM THE PROTOCOL ................................ ................................ ..42 
11. STUDY TERMINATION ................................ ................................ ........................... 43 
12. PROCEDUR E FOR HANDLING PRODUCT QUALITY COMPLAINTS .............. 44 
13. ADVERSE EVENTS ................................ ................................ ................................ ...45 
13.1.  Definitions and Classifications ................................ ................................ ............. 45 
13.2.  Assessing Adverse Events ................................ ................................ .................... 47 
13.2.1.  Causality Assessment ................................ ................................ .................... 47 
13.2.2.  Severity Assessment ................................ ................................ ...................... 48 
13.3.  Documentation and Follow -Up of Adverse Events ................................ .............. 48 
13.4.  Reporting Adverse Events ................................ ................................ .................... 50 
13.4.1.  Reporting Adverse Events to Sponsor ................................ .......................... 50 
CR-6420, v1.0
Page 3 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4.2.  Reporting Adverse Events to the Res ponsible IEC/IRB and Health Authorities
……………………………………………………………………………… 51 
13.5.  Event of Special Interest ................................ ................................ ....................... 51 
13.6. Reporting of Pregnancy ................................ ................................ ........................ 51 
14. STATISTICAL METHODS ................................ ................................ ........................ 51 
14.1.  General Considerations ................................ ................................ ......................... 51 
14.2.  Sample Size Justification ................................ ................................ ...................... 51 
14.3.  Analysis Populations ................................ ................................ ............................ 52 
14.4.  Level of Statistical Significance ................................ ................................ ........... 52 
14.5.  Primary Analysis ................................ ................................ ................................ ..52 
14.6.  Seco ndary Analysis ................................ ................................ .............................. 52 
14.7.  Other Exploratory Analysis ................................ ................................ .................. 52 
14.8.  Interim Analysis ................................ ................................ ................................ ...52 
14.9.  Procedure for Handling Missing Data and Drop -Outs ................................ ......... 53 
14.10.  Procedure for Reporting Deviations from Statistical Plan ................................ ...53 
15. DATA HANDLING AND RECORD KEEPING/ARCHIVI NG................................ 53 
15.1.  Electronic Case Report Form/Data Collection ................................ ..................... 53 
15.2.  Subject Record ................................ ................................ ................................ ......53 
15.3.  Trial Registration on ClinicalTrials.gov ................................ ............................... 54 
16. DATA MANAGEMENT ................................ ................................ ............................. 54 
16.1.  Access to Source Data/Document ................................ ................................ ........ 54 
16.2.  Confidentiality of Information ................................ ................................ .............. 54 
16.3.  Data Quality Assurance ................................ ................................ ........................ 54 
16.4.  Data Monitoring Committee (DMC) ................................ ................................ ....55 
17. CLINICAL MONITORING ................................ ................................ ........................ 55 
18. ETHICA L AND REGULATORY ASPECTS ................................ ............................ 55 
18.1.  Study -Specific Design Considerations ................................ ................................ .55 
18.2.  Investigator Responsibility ................................ ................................ ................... 56 
18.3.  Independent Ethics Committee or Institutional Review Board (IEC/IRB) .......... 56 
18.4.  Informed Consent ................................ ................................ ................................ .57 
18.5.  Privacy of Personal Data ................................ ................................ ...................... 57 
19. STUDY RECORD RETENTION ................................ ................................ ................ 58 
20. FINANCIAL CONSIDERATIONS ................................ ................................ ............ 59 
21. PUBLICATION ................................ ................................ ................................ ........... 59 
CR-6420, v1.0
Page 4 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
22. REFERENCES ................................ ................................ ................................ ............ 60 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) .....61 
APPENDIX B: PATIENT INSTRUCTION GUIDE ................................ ............................. 70 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ................................ ......... 71 
APPENDIX D: ................................ ....100 
 LENS FITTING CHARACTERISTICS ................................ ............................. 101 
 SUBJECT REPORTED OCULAR SYMPTOMS ................................ .............. 107 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
................................ ................................ ................................ ................................ ............... 109 
 BIOMICROSCOPY SCALE ................................ ................................ .............. 115 
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION ......................... 121 
 TORIC FIT EVALUATION ................................ ................................ ............... 126 
 ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE ......131 
 PATIENT REPORTED OUTCOMES ................................ ................................ 135 
 LENS INSERTION AND REMOVAL ................................ .............................. 137 
 VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING ................................ ................................ ................................ .............................. 140 
APPENDIX E: VWI -0081 GUIDELINE S FOR COVID -19 RISK MITIGATION ............ 149 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE ........................ 160 
 
LIST OF TABLES
Table 1: Test Articles ................................ ................................ ................................ .............. 22 
Table 2: Ancillary Supplies ................................ ................................ ................................ ....23 
Table 3: Time and Events ................................ ................................ ................................ ....... 25 
Table 4: Disallowed systemic medications ................................ ................................ ............. 41 
Table 5: Disallowed systemic antihistamines ................................ ................................ ......... 42 
Table 6: Examples of major and minor protocol deviations ................................ ................... 43 
 
LIST OF FIGURES
Figure 1: Study Flowchart ................................ ................................ ................................ ......14 
 
CR-6420, v1.0
Page 5 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL TITLE, NUMBER, VERSION  AND DATE  
Title: Evaluation of ACUVUE OASYS® 1 -Day for Astigmatism Lenses Produced on a New 
Manufacturing Line
Protocol Number: CR-6420
Version: 1.0
Date: 05 November 2020
SPONSOR NAME AND ADDRES S 
Johnson & Johnson Vision Care , Inc. (JJVC)
7500 Centurion Parkway 
Jacksonville, FL 32256
MEDICAL MONITOR  
The Medical Monitor must be notified by the clinical institution/site by e -mail or telephone 
within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be contacted 
during business hours for adverse event questions. General study related questions should be 
directed towards your assigned clinical research associate.
The Medical Monitoring Plan is maintained as a separate document and inc luded in the Trial 
Master File.
 
CR-6420, v1.0
Page 6 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
AUTHORIZED SIGNATURES  
The signature sbelow constitutes the approval of this protocol and the attachments and provide 
the necessary assurances that th is trial will be conducted ac cording to all stipulations of the 
protocol, including all statement s regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. federal regulations,4ISO 14155 ,1ICH guidelines,2
and the Declaration of Helsinki.3
Author & Study 
Responsible Clinician
See Electronic Signature Report 
DATE
Clinical Operations 
Manager See Electronic Signature Report
DATE
Biostatistician See Electronic Signature Report
DATE
Data Management See Electronic Signature Report
DATE
Medical Safety 
Officer See Electronic Signature Report
DATE
Reviewer See Electronic Signature Report
DATE
Approver See Electronic Signature Report
DATE
 
CR-6420, v1.0
Page 7 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
CHANGE HISTORY  
Version Originator Description of Change(s) and Section 
Number(s) AffectedDate
1.0 Original document. 05 Nov 2020
CR-6420, v1.0
Page 8 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SYNOPSIS  
Protocol Title Evaluation of ACUVUE OASYS® 1-Day for Astigmatism 
Lenses Produced on a New Manufacturing Line
Sponsor JJVC, 7500 Centurion Parkway, Jacksonville, FL  32256
Clinical Phase Descriptive study phase: post-market
Design control phase: post-marketing, phase 4
Trial Registration This study will be registered on ClinicalTrials.gov by the 
Sponsor
Test Article(s) Approved Products: 
Test: ACUVUE OASYS®1-Day for Astigmatism contact 
lenses produced on a recently qualified manufacturing line 
(TAM 24).
Control: ACUVUE OASYS®1-Day for Astigmatism contact 
lenses produced on previously established manufacturing 
lines.
Wear and Replacement 
SchedulesWear Schedule: daily wear
Replacement Schedule: daily disposable
Objectives Primary Objectives
Toevaluate the clinical performance of ACUVUE OASYS®
1-Day for Astigmatism contact lenses produced o n a recently 
qualified manufacturing line relative to lenses produ ced on 
previously established lines. 
Study Endpoints Observational endpoints:
xCLUE comfort, vision and handling at fitting and 
following 7(±2) days of wear
xHigh luminance, high contrast (HLHC) logMAR 
visual acuity measured using ETDRS acuity charts at 
follow-up
xLens orientation at 1 and 3 minutes following insertion
xMean and standard deviation of settled lens 
orientation, as calculated from repeated measures of 
signed lens orientation at fitting and follow- up visits.  
All endpoints will be summarized  using descriptive statistics 
only; no formal hypothesis testing will be conducted.
CR-6420, v1.0
Page 9 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Study Design This is a bilateral, dispensing, randomized, controlled, double 
masked, 2×2 cross -over study. Each subject will be randomly 
assigned to one of two wear sequences (test followed by 
control or control followed by test). Each wear period will be 7(±2) days, with a 7(±2) day washout period between wear periods. There will be a total of 4 visits:Visit 1: Screening, baseline evaluation and lens fit #1 Visit 2: Follow
-up evaluation for first lens
Visit 3: Continuance, lens fit #2
Visit 4: Follow -up evaluation for second lens
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main observations (Figure 1).
Sample Size This study will have an e nrollment target of approximately 66 
subjects, with a target of at least 60 to complete (assuming a 
dropout rate of 10%).
Study Duration Total study duration including the enrollment period is 
anticipated to be approximately 8 weeks.
Anticipated Study 
PopulationSubjects will be habitual soft contact lens wearers with 
bilateral astigmatism who are between 18 and 39 years of age (inclusive).
CR-6420, v1.0
Page 10 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria -
InclusionPotential subjects must satisfy of all the following criteria to 
be enrolled in the study.
Inclusion Criteria following Screening
The subject must:
1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the form. 
2. Appear able and willing to a dhere to the instructions set 
forth in this clinical protocol.
3.Be between 18 and 39 (inclu sive) years of age at the time 
of screening.
4.By self- report, habitually wear soft contact lenses in both 
eyes in a daily reusable or daily disposable wear modality 
(i.e. not extended wear modality). Habitual wear is defined 
as a minimum of 6 hours of wear per day, for a minimum 
of 2 days per week during the past month.
5. Possess a wearable pair of spectacles that provide 
correction for distance vision.
Inclusion Criteria following Baseline Evaluation
The subject must:
6.Have the spherical component of their vertex- corrected 
distance refraction must be between -0.875 to - 4.625 DS 
(inclusive) in each eye.
7. Have the magnitude of the cylindrical component of their 
vertex- corrected distance refraction between 0.625 DC 
and 1.625 DC in both eyes.
8.Have the cylinder axis of their distance refraction between 
165° and 15° (i.e., 180±15°, inclusive) or between 75° and 
105° (i.e., 90±15°, inclusive) in each eye.  
9. Have best corrected monocular distance visual acuity of 
20/30 or better in each eye.
CR-6420, v1.0
Page 11 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria –
ExclusionPotential subjects who meet any of the following criteria will 
be excluded from participating in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating.
2.Be diabetic.
3.Be currently us ing any ocular medications or have any 
ocular infection of any type.
4.By self- report, have any ocular or systemic disease, 
allergies, infection, or use of medication that might 
contraindicate or interfere with contact lens wear, or 
otherwise compromise stud y endpoints, including 
infectious disease (e.g., hepatitis, tuberculosis), 
contagious immunosuppressive disease (e.g., Human 
Immunodeficiency Virus [ HIV]), autoimmune disease 
(e.g. rheumatoid arthritis, Sjögren’s syndrome), or history 
of serious mental illness or seizures. See section 9.1 for 
additional details regarding excluded systemic 
medications. 
5. Have habitually worn rigid gas permeable (RGP) lenses, 
orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, 
SoftPerm) within the past 6 months.
6. Be currently wearing monovision or multifocal contact 
lenses.
7. Be currently wearing lenses in  an extended wear modality.
8.Have a history of strabismus or amblyopia.
9. Be an employee (e.g., Investigator, Coordinator, 
Technician) or immediate fami ly member of an employee 
(including partner, child, pa rent, grandparent, grandchild 
or sibling of the employee or their spouse) of the clinical 
site.
10.Have participated in a contact lens or lens care product 
clinical trial within 7 days prior to study enrollment.
Exclusion Criteria following Baseline Evaluation
The subject must not:
11.Have clinically significant (g rade 3 or higher on the FDA 
grading scale) sli t lamp findings (e.g., corneal edema, 
neovascularization or stain ing, tarsal abnormalities or 
bulbar injection) or other corn eal or ocular disease or 
abnormalities that contraindica te contact lens wear or may 
otherwise compromise study endpoints (including
entropion, ectropion, chalazia, recurrent styes, glaucoma, 
history of recurrent corneal eros ions, aphakia, moderate or 
above corneal distortion, herpetic keratitis). 
CR-6420, v1.0
Page 12 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
12. Have fluctuations in vision due to clinically significant dry 
eye or other ocular conditions.
13.Have had or have planned (within the study period) any 
ocular or intraocular surgery (e.g., radial keratotomy, 
PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
Disallowed 
Medications/Interventions Subjects will not be eligible to  enroll if they are taking any 
ocular medications, or any systemic medications that would 
normally contraindicate contact lens wear or may otherwise 
compromise study endpoints . See section 9.1 for details 
regarding disallowed systemic medications.
Measurements and 
ProceduresThe key procedure associated w ith the primary and secondary 
endpoints for this study will be the evaluation of subjective 
comfort using the CLUE questionnaire at follow -up. 
Other measurements and proce dures related to observational 
endpoints will include:
- Completion of the CLUE que stionnaire at fitting and 
follow-up
- Measurement of HLHC VA using ETDRS charts at follow-
up
-Measurement of lens orientation at 1- and 3- minutes
following insertion, and following settling
Microbiology or Other 
Laboratory TestingNot applicable for this study.
Study Termination The occurrence of one or more Unanticipated Adverse Device 
Effect (UADE), or any SAE where relationship to study agent 
cannot be ruled out, will result in stopping further dispensing investigational product. In the event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the Principal 
Investigator before any further subjects are enrolled.
Ancillary Supplies/ Study-
Specific MaterialsLens cases, fluorescein strips and preservative-free rewetting
drops / artificial tears will be supplied for use as needed.  
Principal Investigator(s) 
and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.
CR-6420, v1.0
Page 13 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Figure 1: Study Flowchart
Visit 1: Screening
Statement of Informed Consent
Demographics
Medical History & Concomitant Medications
Habitual Contact Lens Information
Eligibility at Screening
Baseline Evaluation
Subject Reported Ocular SymptomsEntrance visual acuity
Spherocylindrical refraction and distance visual acuity
Slit lamp biomicroscopy findings
Eligibility after Baseline
Baseline CLUE questionnaire (habitual lenses)
Lens Fitting (#1 through #3)
Lens assignment and insertion
Timed rotation assessments, lens settling
Toric and general fit assessment
Spherical over- refraction, modification if required
CLUE post-fit questionnaire
Additional samples of toric lens orientation
Lenses dispensed for 7 r2 days
Follow-up (#1 through #3)
CLUE follow-up questionnaire
ETDRS HLHC visual acuity
Record lens orientation
Additional samples of toric lens orientationLens removal
Biomicroscopy
Schedule next visitContinuance
Review med history and medications
Subject reported ocular symptoms
Entrance VA and biomicros copy
Confirm continuing eligibility
Final Evaluation
Spherocylindrical refraction
Completion status
Biomicroscopy (if discontinued early)After follow-up #1
After follow-up #2Washout Period
A washout period of 7r2 days duration 
will be observed between wear periods
CR-6420, v1.0
Page 14 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
COMMONLY USED ABBREVIATIONS , ACRONYMS  AND DEFINITIONS OF 
TERMS  
Add Near addition ;theadditional power required for near vision correction
ADE Adverse Device Effect
ADHD Attention Deficit Hyperactivity Disorder
AE Adverse Event/Adverse Experience
AO1DfA ACUVUE OASYS® 1 -DAY with HydraLuxe™ TECHNOLOGY for 
ASTIGMATISM
AOfA ACUVUE OASYS® 2 -WEEK for ASTIGMATISM
BSCVA Best Spectacle Corrected Visual Acuity
CFR Code of Federal Regulations
CLUE Contact Lens User Experience
COM Clinical Operations Manager
CRA Clinical Research Associate
CRF Case Report Form
CRO Contract Research Organization
D Diopter
DMC Data Monitoring Committee
eCRF Electronic Case Report Form
EDC Electronic Data Capture
ESD Eyelid Stabilized Design
ETDRS Early Treatment Diabetic Retinopathy Study
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
HIV Human Immunodeficie ncy Virus
IB Investigator’s Brochure
ICH The International Council for Harmonization
IDE Investigational Device Exemption
IEC Independent Ethics Committee
IRB Institutional Review Board
ISO International Organization for Standardization
ITT Intent -to-Treat
JJVC Johnson & Johnson Vision Care, Inc.
LASIK Laser -Assisted in Situ Keratomileusis
LogMAR Logarithm of Minimal Angle of Resolution
OD Right Eye
OS Left Eye
OU Both Eyes
PIG Patient Instruction Guide
PQC Product Quality Complaint
PRK Photorefractive Keratectomy
PRO Patient Reported Outcome
QA Quality Assurance
CR-6420, v1.0
Page 15 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SAE Serious Adverse Event/Serious Adverse Experience
SAP Statistical Analysis Plan
SAS Statistical Analysis System
SD Standard Devia tion
UADE Unanticipated Adverse Device Effect
USADE Unanticipated Serious Adverse Device Effect
VA Visual Acuity
1.INTRODUCTION AND BACKGROUND  
Anew manufacturing line (TAM 24) has b een installed at JJVC to produce ACUVUE 
OASYS® 1 -DAY with HydraLuxe™ TEC HNOLOGY for ASTIGMATISM (AO1DfA) 
lenses. Compared to previously validated AO1DfA production lies, theTAM 24 line features 
several minor changes t o production equipment and processes. Lens c haracterization using 
non-clinical test methods has demonstrated that the AO1DfA lenses produced on TAM 24 are 
indistinguishable from lenses produced on previously validated lines, thus there is no
expectation ofimpact on clinical performance or need for clinical validation ,however there is 
a desire to perform a post -market monitoring study to provide a baseline of clinical data for 
lenses produced on this new manufacturing platform .
1.1. Name and Descriptions of Investigational Products  
This study will evaluate AO1DfA lenses produced on the TAM 24 manufacturing line and 
AO1DfA lenses produced on previously validated commercial production lines. Further details 
about the test articles are found in section 6.1of this protocol.
1.2. Intended Use of Investigational Products  
The intended use of the investigati onal product is the correction of astigmatism and associated 
myopi c refractive error .Study lenses will be worn bilater ally in a daily wear, daily dis posable 
modality for at least 8 hours per day. Each wear period will be  7±2 (i.e., 5 to 9) days in duration, 
and subjects will wear lenses for at least 5 da ys per week during each wear period. Two wear 
periods will be completed, with a washout period of 7±2days between the wear periods.
1.3. Summary of Findings from Nonclinical Studies  
Not Applicable –marketed product only.
1.4. Summary of Known Risks and Benefits to Human Subjects  
The anticipated clinical benefit of the investigational lenses will be the correctio n of refractive 
error. The risks associated with use of the investigati onal lenses are considered to be equivalent 
to those associated with other commercial soft contact lenses worn in the same modality (i.e. 
daily disposable).  
Comprehensive risk and be nefit information regarding the AO1DfA lens are included in the 
AO1DfA package insert (Appendix C).
CR-6420, v1.0
Page 16 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
1.5. Relevant Literature Referen ces and Prior Clinical Data  Relevant to Proposed 
Clinical Study  
The AO1DfA lens material (senofilcon A) has an extensive safety history and the AO1DfA 
lenshas been marketed in the US and Europe since 2017 with no incidence of recalls .
For further details regarding references and prior data relevant to the AO1DfA lens, refer to 
theAO1DfA package insert (Appendix ).
2.STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES  
2.1. Objectives  
Primary Objective
Toevaluate the clinical performance of ACUVUE OASYS®1-Day for Astigmatism contact 
lenses produced on a recently qualified manufacturing line relative to lensesproduced on 
previously established lines .
2.2. Endpoints  
The observational endpoints for this study will be :
xCLUE comfort, vision and handling at fitting and following 7(±2) days of wear
xHigh luminance, high contrast (HLHC) logMAR visual acuity measured using ETDRS 
acuity charts at follow -up
xLens orientation at 1 and 3 minutes following i nsertion
xMean and standard deviation of settled len s orientation, as calculated from repeated 
measures of signed lens orientation at fitting and follow -up visits.  
2.3. Hypotheses  
All endpoints will be summarized using descriptive statistics only; no formal hypothesis testing 
will be conducted.
3.TARGETED STUDY POPULATION  
3.1. General Characteristics  
Thetarget population for this study will be healthy adult soft contact lens wearers between 18 
and 39 years of age with binocular myopic astigmatism.  
3.2. Inclusion Criteria  
Poten tial subjects must satisfy all of the following criteria to be enrolled in the study:
CR-6420, v1.0
Page 17 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Inclusion Criteria following Screening
The subject must:
1.Read, understand, and sign the STATEM ENT OF INFORMED CONSENT and 
receive a fully executed copy of the form .
2.Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3.Be between 18 and 39 (inclusive) years of age at the time of screening.
4.By self -report, habitually wear soft contact lense s in both eyes in a daily reusable or 
daily disposable wear modality (i.e. not ex tended wear modality). Habitual wear is 
defined as a minimum of 6hours of wear per day, for a minimum of 2days per week 
during the past month.
5.Possess a wearable pair of spectacles that provide correction for distan ce vision.
Inclusion Criteria following Baseline Evaluation
The subject must:
6.Have t he spherical component of the irvertex -corrected distance refraction must be 
between -0.875 to -4.625 DS (inclusive) in each eye.
7.Have t he magnitude of the cylindrical co mponent of their vertex -corrected distance 
refraction between 0. 625DC and 1.625 DC in both eyes .
8.Have the cylinder axis of their distance refr action between 165° and 15° (i.e. ,180±15°, 
inclusive) or between 75 °and 105 ° (i.e. ,90±15°, inclusive) in each eye.  
9.Have best corrected monocular distance visual acuity of 20/30 or better in each eye.
3.3. Exclusion Crite ria 
Potential subjects who meet any of the following cr iteria will be excluded from participating 
in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating.
2.Be diabetic.
3.Be currently using any ocular me dications or have any ocular infection of any type.
4.By self -report, have any ocular or systemic disease, allergies, infection, or use of 
medication that might contraindicate or interf ere with contact lens wear, or otherwise 
compromise study endpoints, incl uding infectious disease (e.g., hepatitis, tuberculosis), 
contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [ HIV]), 
autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), or history of 
serious mental illness or seizures. See section 9.1for additional details regarding 
excluded systemic medications. 
5.Have habitually worn rigid gas permeable (RGP) lenses, orthokeratol ogy lenses, or 
hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
6.Be currently wearing monovision or multifocal contact lenses.
7.Be currently wearing lenses in an extended wear modality.
8.Have a history of strabismus or amblyopia.
CR-6420, v1.0
Page 18 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
9.Be an empl oyee (e.g., Investigator, Coordinator, Technician) or immediate family 
member of an employee (including partner, ch ild, parent, grandparent, grandchild or 
sibling of the employee or their spouse) of the clinical site.
10.Have participated in a contact lens or lens care product clinical trial within 7 days prior 
to study enrollment.
Exclusion Criteria following Baseline Evaluation
The subject must not:
11.Have clinically significant ( grade 3 or higher on the FDA grading scale) slit lamp 
findings (e.g., corneal edema, neovasculariz ation or staining, tarsal abnormalities or 
bulbar injection) or other corne al or ocular disease or abnorm alities that contraindicate 
contact lens wear or may o therwise compromise study endpoints (including entropion, 
ectropion, chalazia, recurrent styes, glauco ma, history of recurrent corneal erosions, 
aphakia, moderate or above corneal distortion, herpetic keratitis). 
12.Have fluctuations in vision due to clinica lly significant dry eye or other ocular 
conditions. 
13.Have had or have planned (within the study period) any ocular or intraocular surgery 
(e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulat ion, etc.).
3.4. Enrollment Strategy  
Study subjects will be recruited from the Inst itution/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials. 
4.STUDY DESIGN AND RATIONALE  
4.1. Description of Study Design  
This will be a 4-visit, randomized, controlled, double -masked, bilateral wear, dispensing, 2 ×2
crossover study. Each subject will be randomized into one of twounique sequences to wear 
twodifferent study lenses one at a time ov er twowear periods (test/control or control/test) .
During each wear period the lenses will be worn bilaterally for 1 week (7 r2 days) in a daily 
disposable modality .Study lenses will be worn for a mi nimum of 8 hours per day and at least 
5 days per week du ring the wear period. Subjective  comfort, vision and handling will be 
assessed using the CLUE questionnaire at both fitting and follow -up visits for each wear 
period. HLHC VA will be assessed at the follow -up evaluation using ETDRS charts. There 
will be a washout period of 7r2 days duration between wear periods. Subjects will not have 
access to the study lenses following completion of the protocol.
4.2. Study Design Rationale  
A 2×2 crossover study design was chosen  to allow efficient comparison o f the test articles with 
minimal sample size. A washout period will be included to mitigate any carryover effects. 
CR-6420, v1.0
Page 19 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
The prescribed wear schedule (7 r2 days, minimum of 8 hours per day, minimum of 5 days per 
week) was chosen as this is representative of a t ypical wear schedule for contact lens wearers. 
4.3. Enrollment Target and Study Duration  
This study will have an enrollment target of approximately 66 subjects, with a target of at least 
60to complete. The study will be conducted at up to 5 clinical sites , where the enrollment 
target for each site will be approximately 14 subjects. A subject  will be considered enrolled 
upon signing of the informed consent form.  
There will be 4 visits in total per subject;  total study duration including the enrollment perio d
is expected to be approximately 8 weeks. Subjects who are discontinued prior to the final 
evaluation may b e replaced at the discretion of the study sponsor .The investigation will end 
at the time that the study data is hard locked.
5.TEST ARTICLE ALLOCATIO N AND MASKING  
5.1. Test Article Allocation  
This study will be a randomized, double -masked, 2 ×2 crossover design. Subjects will be 
randomized into one of 2 unique sequence groups  (test/control or control/test) in a 1:1 
allocation ratio to wear two different stu dy lens designs (test and control designs) one at a time 
bilaterally over 2 wear periods. 
Use of the test articles will be randomized us ing a randomization scheme supplied by the study 
biostatistician.  The randomized assi gnment of subjects will be perfo rmed at the first visit prior 
to the first fitting. C linical sites will follow the randomization scheme provided and will not 
pre-select or assign subjects. The following must have occurred prior to randomization:
xInformed consent must have been obtained
xThe subject must have met all inclusion and exclusion criteria
xThe subject history and baseline information must have been collected
Randomly -permuted block randomization will be used to avoid bias in the assignment of 
subjects to treatment and to enhance the validity of statistical  comparisons across treatment 
groups.
When dispensing test articles, the following steps should be followed to maintain 
randomization codes:
1.Investigator or designee (documented on the Delegation Log) will consult the 
randomization scheme (lens fitting schedule) to obtain the test article assignment for 
that subject prior to dispensing .
2.Investigator or designee will record the subj ect’s number on the appropriate line of the 
randomization scheme (lens fitting schedule).
3.Investigator or designee will pull the approp riate test articles from the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed 
CR-6420, v1.0
Page 20 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
outside the clinical site) or not, must be  recorded on the Test Article Accountabili ty 
Log in the “Dispensed” section .
5.2. Masking  
To reduce the possibility of bias, this will be a double -masked trial; subjects, investigators and 
technicians will notbe aware of the identity of the assigned lenses. Every attempt will be made 
to keep the clini cal trial personnel involved in the study ( including data management, the study 
biostatistician and clinical operations personnel ) unaware of the identity of the assigned study 
lenses. The identity of the study lenses will be masked by having the blister p acks labeled with 
the study number, lot number, sphere power, cylinder power, axis, expiration date and 
randomization code. Only the unmasked Biostatistician generating the randomization scheme 
(lens fitting schedule) will have access to the decode informa tion that allows matching of the
randomization codes to the investigational articles. The medical monitor will also have access 
to the decode information in case breaking th e mask is necessary for the urgent medical 
treatment of a subject.
5.3. Procedures for Maintaining and Breaking the Masking  
Under normal circumstances, the mask should not be broken until all subjects have completed 
the study and the datab ase is finalized. Otherwise, the mas k should be broken only if specific 
emergency treatment/course of action would be dictated by kno wing the treatment status of the 
subject. In such cases, the Investigator may, in  an emergency, contact the medical monitor. In 
the event the mask is broken, the Sponsor must be informed as soon as possibl e. The date, 
time, and reason for the unmasking must be docum ented in the subject record. The Investigator 
is also advised not to reveal the study trea tment assignment to the clinical site or Sponsor 
personnel. 
Subjects who have had their treatment assig nment unmasked are expected to return for all 
remaining scheduled evaluations. Subjects who are discontinued may be replaced at the 
discretion of the study sponsor .
6.STUDY INTERVENTION  
6.1. Identity of Test Articles  
The following contact lenses will be used in this study:
CR-6420, v1.0
Page 21 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Table 1: Test Articles
In total, both test and control lenses w ill be available in 270 unique lens power s (15sphere
power s×3cylinder powers ×6 axes) .
The total number of test lenses to be used in th is study (not including lenses that are replaced 
due to droppage, loss or damage) is expected to be approximat ely 924 lenses (target enrollment 
of 66 subjects ×2 eyes per subject ×7 day wear period). Test a nd control lenses will be worn 
in a 1:1 ratio, thus the number of control lenses to  be used is expected to be approximately the 
same (924 lenses). Test Control
Test Article Form Soft contact lens
Design / Description AO1DfA manufactured 
on TAM 24 lineAO1DfA manufactured on 
previously validated lines
Manufacturer Johnson & Johnson Vision Care, Inc.
Packaging Form Blister packaging in sterile packing solution
Packaging Solution Optimized Borate Buffer (OBB) solution
Lens Material senofilcon A (C3)
Sphere Powers (DS) -1.00 to -4.50 in 0.25 steps
Cylinder Powers (DC) -0.75, -1.25
Cylinder Axes (°) 10, 80, 90, 100, 170, 180
Nominal Water Content 
(%)41
Nominal Base Curve (mm) 8.5
Lens Diameter (mm) 14.3
Fiducial marks 6 and 12 o’clock fiducial lines
Dk (Fatt method, boundary 
corrected, edge corrected, 
×10-11[cm2/sec] [ml O 2/ml
× mm Hg] at 35°C)103
Modality in Current Study Daily wear
Replacement Frequency in 
Current StudyDaily disposable
,  
CR-6420, v1.0
Page 22 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.2. Ancillary Supplies/Products  
The following solutions will be used in this study:
Table 2: Ancillary Supplies
Non-Preserved Rewetting Drops 
Solution Name/DescriptionSingle use Eye-
Cept®Rewetting 
Drops LacriPure Saline 
SolutionScleralFil 
Preservative Free 
Saline Solution
Manufacturer Optics Laboratory Menicon Bausch & Lomb
Preservative None None None
Lens cases and fluorescein stri ps (either 0.6 mg or 1.0 mg) will be supplied for use as needed.
6.3. Administration of Test Articles  
Test articles will be dispensed to subject smeeting all eligibility requirements, including any 
dispensing requirements set forth in this clin ical protocol. Subjects will be dispensed an 
adequate supply of test articles to comple te the study. Lost or damaged test articles may be at 
the discretion o f the investigator and/or the sponsor.
6.4. Packaging and Labeling  
The test articles will be packaged in blister packages as the primary packaging and placed into 
plastic bags as secondary packaging .Control lenses will be over -labeled. Representative
sample l abels for the primary and secondary packaging are shown below:
Primary Packaging Secondary Packaging
CR-6420, v1.0
Page 23 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.5. Storage Conditions  
Test articles will be maintained at ambient temper atures at the clinical site. Test articles must 
be kept under secure conditions.
6.6. Collection and Storage of Samples  
No samples will be collected as part of the study procedures. When possible, any lens or test 
article associated with an Adverse Event and/or a Product Quality Complaint must be retained 
and stored in a glass vial with moderate solution pending directions from the sponsor for 
potential return to JJVC.
6.7. Accountability of Test Articles  
JJVC will provide the Investigator with sufficient  quantities of study articles and supplies to 
complete the investigation. The In vestigator is asked to retain all lens shipment documentation 
for the test article accountability records. 
Test article smust be kept in a locked storage cabinet, accessible only to those assigned by the 
Investigator for dispensing. The Investigator may delegate this activity to authorized study site 
personnel listed on the Site Delegation Log. All test articles must be accounted. This includes:
1.What was dispensed for the subject for trial fitting, to wear out of the office, or issued 
for the subject to r eplace appropriately between visits .
2.What was returned to the Investigator unused ,including expired or malfunctioning 
product .
3.The number and reason for unplanned replacements .
The Investigator will collect all unused test articles  from the subjects at the end of the subject’s 
participation. Subject returned unused test articles must be separated from the clinical study 
inventory of un -dispensed test articles and must be labeled with the subject number and date 
of return. Following final reconciliation of test articles by the monitor, the Investigator or 
monitor will return all unused test articles to JJVC.
If there is a discrepancy between th e shipment documents and the contents , contact the study 
monitor immediately .
          
CR-6420, v1.0
Page 24 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
7.STUDY EVALUATIONS  
7.1. Time and Event Schedule  
Table 3:Time and Events
Visit InformationVisit 1
Screening, 
Baseline, 
Lens Fitting 
#1Visit 2
Follow -up #1Visit 3
Continuance, 
Lens Fitting 
#2Visit 4
Follow- up
#2, Final 
Evaluation
Time Point Day 07 ± 2 days 
following 
Visit 27 ± 2 days 
following 
Visit 37 ± 2 days 
following 
Visit 4
Minimum lens wear time 
immediately prior to visitMust wear 
habitual 
lenses1 hour (study 
lenses)No 
requirement 
for this visit1 hour (study 
lenses)
Estimated Visit Duration 2.5 hours 1.5 hours 1.5 hours 1.5 hours
Statement of informed consent x
Demographics x
Medical history/concomitant 
medicationsxxxx
Habitual contact lens information x
Eligibility at Screening x
Subject reported ocular 
symptomsxxxx
Baseline PRO questionnaire x
Entrance visual acuity x x x x
Remove habitual lenses x x
Subjective Sphero-Cylindrical 
Refractionxx
Slit Lamp Biomicroscopy x x x x
Eligibility at Baseline x
Lens Selection x x
Lens insertion and timed rotation 
assessmentsxx
Lens settling x x
Toric fit assessment x x
General fit assessment x x
Spherical over-refraction x x
Lens modification (if necessary) x x
Post-fit PRO questionnaire x x
Additional samples of toric lens 
orientation (performed twice)xxxx
Exit visual acuity x x x
Dispensing criteria x x
Dispensing instructions x x
CR-6420, v1.0
Page 25 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit InformationVisit 1
Screening, 
Baseline, 
Lens Fitting 
#1Visit 2
Follow -up #1Visit 3
Continuance, 
Lens Fitting 
#2Visit 4
Follow- up
#2, Final 
Evaluation
Time Point Day 07 ± 2 days 
following 
Visit 27 ± 2 days 
following 
Visit 37 ± 2 days 
following 
Visit 4
Minimum lens wear time 
immediately prior to visitMust wear 
habitual 
lenses1 hour (study 
lenses)No 
requirement 
for this visit1 hour (study 
lenses)
Estimated Visit Duration 2.5 hours 1.5 hours 1.5 hours 1.5 hours
Schedule next visit x x x
Wear time and compliance x x
Follow-up PRO questionnaire x x
Distance HLHC visual acuity 
using ETDRS chartsxx
Toric lens orientation x x
Lens removal x x
Continuance x
Subject completion status x
7.2. Detailed Study Procedures  
VISIT 1
Subjects must wear their habitual contact lenses to this visit.
Visit 1: Screening
Step Procedure Details
1.1 Statement of 
Informed ConsentEach subject must read, understand, and sign 
the Statement of Informed Consent before being enrolled into the study. The Principal Investigator or his/her designee conducting the informed consent discussion must also sign the 
consent form.
Note: The subject must be provided a signed 
copy of this document.
1.2 Demographics Record the subject’s year of birth, age, 
gender, race and ethnicity.
1.3 Medical History and 
Concomitant MedicationsRecord the subject’s medical history and 
concomitant medications.
CR-6420, v1.0
Page 26 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Screening
Step Procedure Details
1.4 Habitual Lenses Record the subject’s habitual lens type, 
parameters, lens care solution, wear modality and approximate prescription date.
1.5 Eligibility after 
ScreeningAll responses to Screening Inclusion Criteria 
questions must be answered “yes” and all responses to Exclusion Criteria must be answered “no” for the subject to be considered eligible. 
If subject is deemed to be ineligible after 
screening, proceed to Final Evaluation and 
complete Subject Disposition. Refraction and Biomicroscopy forms do not need to be completed as part of Final Evaluation.
Visit 1: Baseline
Step Procedure Details
1.6 Subject reported ocular 
symptomsRecord any subject reported ocular symptoms 
reported with regard to their habitual contact 
lenses.  
1.7 Baseline PRO 
questionnaire Ask the subject to fill out the baseline 
questionnaire regarding their experience with 
their habitual contact lenses .
1.8 Entrance visual acuity Record the monocular distance Snellen visual 
acuity for each eye (OD, OS) to the nearest letter 
with the subject’s habitual contact lens correction.  
Subjects must continue unt il at least 50% of the 
letters on a line are read incorrectly.
1.9 Remove habitual 
lensesThe subject’s habitual contact lenses will be 
removed and stored in a lens case, if required. 
CR-6420, v1.0
Page 27 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Baseline
Step Procedure Details
1.10 Subjective sphero-
cylindrical refractionConduct a full spherocylindrical bare eye 
subjective refraction with binocular balance and 
record the resultant monocular visual acuity for 
each eye to the nearest letter.
Note: The duo -chrome test should be used for 
refining the monocular and binocular spherical 
endpoints. This test will be considered to have 
reached the endpoint when the targets on red and 
green backgr ounds appear to be equally sharp. 
However, if the subject’s response changes 
immediately from “red” to “green” with a 
0.25DS change in power, the endpoint will be the most plus power (with “red” target clearer) 
before this reversal.  
1.11 Slit lamp 
biomicroscopyThe FDA Slit Lamp Classification Scale will be 
used to grade findings.  If any slit lamp finding is 
graded as 3 or worse, the visit will be discontinued; 
however, the subject may repeat the baseline 
evaluation (one time) at a later date once the 
condition lessens.  
Should the clearance of the fluorescein need to be 
expedited, preservative free rewetting drops or 
artificial tears may be instilled.
1.12 Eligibility at baseline All responses to Inclusion Criteria questions must 
beanswered “yes” and all responses to Exclusion 
Criteria questions must be answered “no” for the subject to be considered eligible.
If subject is deemed to be ineligible after 
baseline, proceed to Final Evaluation.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.13 Lens selection Assign the study lens based on the randomization 
scheme. Select the fitting lens powers based on 
vertex -corrected subjective refraction for each 
eye, with consideration of the following 
guidelines:
1. Label cylinder axis should be determined by 
rounding the refraction cylinder axis to the 
nearest 10 degrees.  Axis ending in the digit ‘5’ should be rounded towards 180 for eyes with 
with-the- rule astigmatism, or towards 90 for 
eyes with against-the-ru le astigmatism (e.g. 175 
CR-6420, v1.0
Page 28 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
should be rounded to 180, 105 should be 
rounded to 100).  
2. Cylinder power should be chosen based on the 
following table:
3.The fitting lens spherical equivalent (SE) 
power (label sphere power + 1/2 of the label 
cylinder power) should be as close as possible 
to the SE of the vertex- corrected refraction.  If 
the SE of the vertex-corrected refraction is 
exactly halfway between two label SE powers, 
the least minus label power should be fit first.Vertex corrected 
cylinder power (X) 
within the range: 
(DC)Label cylinder power 
to be fit (DC)
-0.625 ≤  X < -1.125 -0.75
-1.125 ≤  X < -1.625 -1.25
1.14 Right eye lens 
insertion Instruct the subject to insert the right-eye lens 
with random orientation.    
If lens is uncomfortable, inspect for damage and 
remove, reinsert or replace as necessary.  
1.15 Timed rotation 
assessments during 
settling periodStart a stopwatch (or suitable smartphone or 
tablet timing app) as soon as the right lens is 
inserted. Record lens rotation (direction and 
magnitude) to the nearest degree at one (1) and three (3) minutes following insertion.  
Note:  All lenses in this study have scribe marks 
at 6 o’clock and 12 o’clock positions and rotation 
measurements are made relative to a vertical 
reference line.  
1.16 Left eye lens insertion Instruct the subject to insert the left-eye lens with 
random orientation.    
If lens is uncomfortable, inspect for damage and 
remove, reinsert or replace as necessary.  
1.17 Timed rotation 
assessments during 
settling periodStart a stopwatch (or suitable smartphone or 
tablet timing app) as soon as the left lens is 
inserted. Record lens rotation (direction and 
magnitude) to the nearest degree at one (1) and 
three (3) minutes following insertion.  
Note:  All lenses in this study have scribe marks 
at 6 o’clock and 12 o’clock positions and rotation 
measurements are made relative to a vertical 
reference line.  
CR-6420, v1.0
Page 29 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.18 Lens settling Allow lenses to settle for a period of at least 
15 minutes following left lens insertion.  
1.19 Toric fit assessment Record for each eye:
1.The rotational position to the nearest 
degree
2. Lens stability with blinks
3. Toric fit acceptability. The toric lens fit 
will be designated as ‘unacceptable’ if 
either:
a.The lens ABSOLUTE ROTATION is 
greater than 20 degrees 
b.The LENS STABILITY WITH 
BLINK is greater than 5 degrees
If one or both lenses demonstrate an unacceptable 
toric fit, the subject will be discontinued (proceed 
to final evaluation).  
1.20 General lens fit 
assessmentThe fitting characteristics of the lens in both eyes 
will be assessed using a slit lamp.  Lens position 
(centration, limbal exposure, edge lift) and 
movement (primary and up gaze as well as push-
up) will be assessed. Fit acceptability is defined as any len
s that does notdisplay the following 
general fit characteristics:
xLimbal exposure (presence of clear cornea) 
in any direction of gaze.
xEdge lift
xInsufficient movement in all three 
movement assessments (primary gaze, up-
gaze and push-up test).  
xExcessive movement in primary gaze
If the general fit is unacceptable for either eye, 
the subject will be discontinued (proceed to exit 
evaluation).  
CR-6420, v1.0
Page 30 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.21 Spherical over-
refractionPerform monocular spherical over-refraction 
using duo -chrome to refine the endpoint as 
described in step 1.10 (the final spherical 
endpoint may be determined binocularly).  
The spherical over -refraction must be plano in 
both eyes to continue .
If a non -plano over- refraction is found in either 
eye, th elens(es) must be refit with the 
indicated change in sphere power .  If the 
indicated lens power is not available for either 
eye (e.g., outside the available SKU range), the 
subject will be discontinued (proceed to final evaluation).  
1.22 Lens modification (if 
necessary)If modification is necessary in one or both eyes, 
select the reason for refitting lenses:
xThe settled lens rotation is such that a 
different cylinder axis would be more 
appropriate (use the LARS rule to 
determine the replacement lens cylinder 
axis)
xThe spherical over- refraction is not plano
xOther (specify reason)
Repeat steps 1.14 through 1.21 for one or both 
eyes, as appropriate.  
A maximum of 2 lens modifications are allowed 
per eye. If, for either eye, the fit is not successful 
after 2 modifications, the subject will be discontinued (proceed to final evaluation).  
1.23 Post-fit PRO 
questionnaireSubjects will complete a PRO questionnaire 
regarding the initial comfort, vision and handling 
of the study lenses.  
1.24 Additional sample of toric lens orientation 
(1)Instruct the subject to leave the consulting room and walk around for at least 2 minutes. Upon their 
return, measure and record the toric lens 
orientation for each eye to the nearest degree .
1.25 Additional sample of 
toric lens orientation 
(2)Repeat the previous step once again.    
1.26 Exit visual acuity Record the exit monocular distance Snellen visual acuity for each eye with the subject wearing the 
study lenses.  
CR-6420, v1.0
Page 31 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.27 Dispensing criteria Lenses may be dispensed if both following 
conditions are met:
1. The monocular distance visual acuity with the 
study lenses is equal to or better than 20/25 in 
each eye.
2. The subject indicates that the comfort and 
vision with the study lenses is acceptable.
If either of these conditions is not met, the subject 
will be discontinued (proceed to exit evaluation).  
1.28 Dispensing 
instructionsIf the study lenses are suitable for dispensing: 
xInstruct the subject to wear the study lenses 
for at least 8 hours per day (in a daily wear / daily disposable modality) on at least 5 days 
of the wear period.  Subjects must not wear 
their habitual lenses at any time during the 
dispensing period .
xProvide the subject with a copy of the Patient 
Instruction Guide.
xPreservative-free rewetting drops are 
permitted, if needed.
xDispense enough lenses for the subject to 
complete the wear period (i.e. up to and 
including their scheduled follow- up visit). At 
the investigator’s discretion, in instances 
where there is a high likelihood of the subject 
needing replacement lenses (e.g., due to 
subject activities, unavailability of subject or 
site during the wear period, high likelihood of 
lens tears, etc.), one additional spare pair may 
be dispensed.
Note: In the event that a subject requires 
additional lenses due to loss or damage, they may 
return to the clinical site for lens replacement. As much as reasonably possible, damaged lenses and 
packaging should be returned to the clinical site 
(in solution, if possible) for shipping to the 
Sponsor. If lens damage is present, complete the 
Product Quality Complaint Form, store the lens in a labeled vial 
with saline and return it to the 
Sponsor.
xEnsure the subject is aware of the correct lens 
power for each eye (label the lenses with R 
and L as appropriate). 
CR-6420, v1.0
Page 32 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
xInstruct the subject to bring their habitual 
spectacles or contact lenses to the next visit (to 
wear following removal of the study lenses).
1.29 Schedule next visit Schedule the follow-up visit to occur in 7 ± 2 
days (counting the day of this visit as day 0, the 
subject may return on day 5 through 9). Ensure 
the subject is instructed to wear the study lenses 
for at least 1 hour immediately prior to attending the follow-up visit.  
VISIT 2
Visit 2 will occur 5 to 9 days following Visit 1. Subjects must present to this visit wearing the 
study lenses in both eyes, and lenses must have been worn for at least 1 hour prior to the visit. 
Subjects should bring their own habitual spectacles or cont act lenses to this visit to wear 
following study lens removal.
Visit 2: Treatment 1 Follow-Up 1
Step Procedure Details
2.1 Wear time and 
complianceRecord the subjects wearing time and comfortable 
wearing time. Subjects must have worn lenses for 
at least 8 hours on at least 5 days during the 
dispensing period, and for at least 1 hour prior to 
attending this visit.  
2.2 Review medical 
history and concomitant 
medicationsRecord any changes to the subject’s medical 
history (including adverse events) or concomitant medications.  
2.3 Subject reported ocular 
symptomsRecord any subject reported ocular symptoms in 
response to a verbal open -ended symptoms 
questionnaire.  
2.4 Follow-up PRO 
questionnaireSubjects will complete a PRO questionnaire to 
assess their experience with the study lenses.  
2.5 Entrance visual acuity Record the entrance Snellen VA for each eye 
while wearing the study lenses.  
CR-6420, v1.0
Page 33 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 2: Treatment 1 Follow-Up 1
Step Procedure Details
2.6 Distance ETDRS 
visual acuityMeasure monocular distance high luminance high 
contrast (HLHC) visual acuity using ETDRS charts at 4 meters. 
Measure each eye using the charts shown in the 
table below:
Condition HLHC
Room 
illumination> 400 lux
Chart luminance 120 - 200 cd/m2
Eye OD OS
ChartsHC-1
HC-2HC-3
HC-4
Recorded letter-by-letter results into EDC.
2.7 Toric lens orientation Record the toric lens orientation for each eye to 
the nearest degree.  
2.8 Additional sample of 
toric lens orientation (1)Instruct the subject to leave the consulting room 
and walk around for at least 2 minutes. Upon their return, measure and record the t
oric lens 
orientation to the nearest degree in each eye.  
2.9 Additional sample of 
toric lens orientation 
(2)Repeat the previous step once again.    
2.10 Lens removal Remove and place both lenses into a lens case 
with saline solution.
Do not discard the lenses until after 
biomicroscopy has been completed.  
2.11 Biomicroscopy The FDA Slit Lamp Classification Scale will be 
used to grade findings.  If any slit lamp finding is graded as 3 or worse, the subject must be 
discontinued, an adverse event will be recorded and 
the subject will be monitored as per the guidelines 
given in section 
13.
Should the clearance of the fluorescein need to be 
expedited, preservative free rewetting drops or 
artificial tears may be instilled.
Study lenses may be discarded if there is no 
reason to store them following biomicroscopy.  
2.12 Exit visual acuity Record the exit monocular distance Snellen visual 
acuity for each eye with the subject wearing their 
habitual correction.  
CR-6420, v1.0
Page 34 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 2: Treatment 1 Follow-Up 1
Step Procedure Details
2.13 Schedule next visit Schedule the next visit (Visit 3) to occur 
following a washout period of 7 ± 2 days 
(counting the day of this visit as day 0, the subject 
may return on day 5 through 9). Subjects may 
wear their habitual lenses during the washout period.  
VISIT 3
Visit 3 will occur 5 to 9 days following Visit 2. Subjects may wear their habitual contact lenses 
to this visit.  
Visit 3: Continuance
Step Procedure Details
3.1 Review medical history 
and concomitant medicationsRecord any changes to the subject’s medical 
history or concomitant medications.  
3.2 Subject reported ocular 
symptomsRecord any subject reporte d ocular symptoms in 
response to a verbal open -ended symptoms 
questionnaire.  
3.3 Entrance visual acuity Record the entrance distance Snellen visual acuity 
for OD and OS with the subject wearing their 
habitual correction.  
3.4 Remove habitual lenses 
(if worn)If worn, the subject’s habitual contact lenses will 
be removed. Lenses may be stored in a lens case, if required.
3.5 Biomicroscopy The FDA Slit Lamp Classification Scale will be 
used to grade findings.  If any slit lamp finding is 
graded as 3 or worse, the subject must be 
discontinued, an adverse event will be recorded 
and the subject will be monitored as per the guidelines given in s
ection 13.
Should the clearance of the fluorescein need to be 
expedited, preservative free rewetting drops or artificial tears may be instilled.
3.6 Continuance Verify that the subject is eligible to continue in the 
study.  
Visit 3: Lens Fitting #2
The steps followed will be the same as t hose listed under Visit 1: Lens fitting #1.
CR-6420, v1.0
Page 35 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
VISIT 4
Visit 4 will occur 5 to 9 days following Visit 3. Subjects must present to this visit wearing the 
study lenses in both eyes, and lenses must have been worn for at least 1 hour prior to the visit.  
Subjects should bring their own habitual spectacles or co ntact lenses to this visit to wear 
following study lens removal.
Visit 4: Follow-Up #3
Step Procedure Details
4.1 Wear time and 
complianceRecord the subjects wearing time and comfortable 
wearing time.  Subjects must have worn lenses for 
at least five continuous 8 -hour periods during the 
dispensing period, and for at least 1 hour prior to 
attending this visit.  
4.2 Review medical 
history and 
concomitant 
medicationsRecord any changes to the subject’s medical 
history (including adverse events) or concomitant medications.  
4.3 Subject reported 
ocular symptomsRecord any subject reported ocular symptoms in 
response to a verbal open -ended symptoms 
questionnaire.  
4.4 Follow-up PRO 
questionnaireSubjects will complete a PRO questionnaire to 
assess their experience with the study lenses. 
4.5 Entrance visual acuity Record the entrance Snellen VA for each eye while 
wearing the study lenses.  
4.6 Distance ETDRS 
visual acuityMeasure monocular distance high luminance high 
contrast (HLHC) visual acuity using ETDRS charts 
at 4 meters. 
Measure each eye using the charts shown in the table 
below:
Condition HLHC
Room 
illumination> 400 lux
Chart luminance 120 - 200 cd/m2
Eye OD OS
ChartsHC-1
HC-2HC-3
HC-4
Recorded letter-by-letter results into EDC.
4.7 Toric lens orientation Record the toric lens orientation for each eye to the 
nearest degree.  
4.8 Additional sample of 
toric lens orientation 
(1)Instruct the subject to leave the consulting room 
and walk around for at least 2 minutes. Upon their 
return, measure and record the toric lens 
orientation to the nearest degree in each eye.  
CR-6420, v1.0
Page 36 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 4: Follow-Up #3
Step Procedure Details
4.9 Additional sample of 
toric lens orientation (2)Repeat the previous step once again.    
4.10 Lens removal Remove and place both lenses into a lens case with 
saline solution.
Do not discard the lenses until after biomicroscopy 
has been completed.  
4.11 Biomicroscopy The FDA Slit Lamp Classification Scale will be 
used to grade findings.  If any slit lamp finding is 
graded as 3 or worse, an adverse event will be 
recorded and the subject will be monitored as per the 
guidelines given in section 13.
Should the clearance of the fluorescein need to be 
expedited, preservative free rewetting drops or 
artificial tears may be instilled.
Study lenses may be discarded if there is no reason 
to store them following biomicroscopy.  
FINAL EVALUATION
The final evaluation will ordinarily take place immediately following the last scheduled 
follow -up visit per the study protocol. It ma y also take place at any point the subject 
discontinues the study or is terminated from the study.
Final Evaluation
Step Procedure Details
F.1 Final Exam Form Indicate if the subject completed the study 
successfully. If subject discontinued from the study, indicate the reason.
F.2 Exit Refraction Perform bare-eye subjective spherocylindrical 
refraction with a phoropter and record the best
-corrected distance visual acuity (OD and
OS)to the nearest letter. 
Note : This step is not necessary if the subject 
was exited due to screen failure.
CR-6420, v1.0
Page 37 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Final Evaluation
Step Procedure Details
F.3 Exit Slit Lamp 
Biomicroscopy (for subjects that are discontinued early)FDA Slit Lamp Classification Scale will be 
used to grade the findings.
If the clearance of the fluorescein needs to be 
expedited, preservative -free rewetting drops 
or saline may be instilled. This step is not 
necessary if the subject was exited due to screen failure.
Note
: This step is not necessary if the subject 
was exited due to screen failure, o ri f
biomicroscopy wasperformed as part of the 
final follow -up visit procedures (i.e., 
immediately prior to the final evaluation).
7.3. Unscheduled Visits  
If, during the investigation, a subject requires an unscheduled visit to the clinical site, the 
following information will be collected ,as appropriate :
xChief complaint prompting the visit. If the re ason is an adverse event, the applicable 
eCRF for the adverse event must be co mpleted and subject record completed as 
appropriate .
xDate and time of the visit and all procedures completed at the unscheduled visit .
xReview of adverse event and concomitant medications .
xDocumentation of any test article dispensed or  collected from the subject, if applicable .
xSlit lamp findings (using the Slit Lamp Classification Scale) .
Ifthe Investigator withdraws a subject from the study, the final study visit case report forms 
must be completed indicating the reason(s) w hy the subject was withdrawn. The subject record 
must be completed documenting th e date and primary reason for withdra wal and the study 
CRA notified.
Any ocular and non -ocular Adverse Events that are ongoing at the time of the study visit will 
be followed by the Investigator, within licensure , until they have resolved, returned to pre -
treatment status, stabilized, or bee n satisfactorily explained. If  further treatment i.e., beyond 
licensure is required, the subject will be refe rred to the appropriate health care provider. 
The following information will be collected during an unscheduled visit.
CR-6420, v1.0
Page 38 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Unscheduled Visit
Step Procedure Details
U.1 Reason for 
unscheduled visitIndicate if the only reason for the visit is that 
the subject requires additional test articles. If 
the reason is other than resupply of 
previously dispensed lenses , specify the 
reason for the visit.
U.2 Chief Complaints (if 
applicable)Record the subject’s chief complaints for 
reasons for the unscheduled visit.
U.3 Adverse Events and 
Concomitant Medications Review
(if applicable)Review any changes to the subject’s medical 
history or concomitant medications from the previous study visit. Record any changes, and 
any adverse events.
U.4 Entrance VA (if 
applicable)Record the entrance distance visual acuity 
(OD, OS) to the nearest letter. 
U.5 Subjective Sphero-
cylindrical Refraction
(if 
applicable)Perform bare-eye subjective spherocylindrical 
refraction with a phoropter (adopt the maximum plus to maximum visual acuity (MPMVA) approach and use the duo
-chrome 
test for binocular balancing) and record the 
best corrected distance visual acuity to the 
nearest letter (OD, OS). 
U.6 Slit Lamp 
Biomicroscopy (if applicable)FDA Slit Lamp Classification Scale will be 
used to grade the findings.  If the clearance of the fluorescein needs to be expedited, 
preservative
-free rewetting drops may be 
instilled.
U.7 Dispensing (if 
applicable)If the subject requires additional lenses to 
complete the wear period and is eligible to do so, provide additional lenses per 
the
dispensing instructions given in the detailed 
study procedures.
U.8 Exit Visual Acuity 
(if applicable)Record the subject’s exit distance visual 
acuity (OD, OS) to the nearest letter. 
Note :If the only reason for the unscheduled visit is that the subject requires additional test 
articles, only the dispensing information needs to be recorded.
7.4. Laboratory Procedures  
Not applicable.
CR-6420, v1.0
Page 39 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
8.SUBJECTS COMPLETION/WITHDRAWAL  
8.1. Completion Criteria  
Subjects are considered to have completed the study if they: 
xprovided informed consent .
xthey are eligible .
xhave not withdrawn/discontinued from the study for any reason described in section 
8.2.
xcompleted all visits through the final visit (visit 4) .
xIf all visits were completed but an addition al visit is considered necessary for subject 
care, follow the requirements for unscheduled vis itsin section 7.3.
8.2. Withdrawal/Discontinuation from the Study  
A subject will be withdrawn from the study for any of the following reasons:
xSubject withdrawal of consent .
xSubject not compliant to protocol .
xSubject lost to follow -up.
xSubject no longer meets eligibility criteria (e.g. the subject becomes pregnant) .
xSubject develops significant or serious adverse events necessitating discontinuation of 
study lens wear 
xSubjects who have experienced a Corneal Infiltrative Event (CIE) .
xInvestigator’s clinical jud gment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment) .
xSubject misse sanystudy visits
xSubject not compliant with study lens wear schedule 
xSubject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit .
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled) .
xComplete the Final Evaluation, indicating the reason that the subject was discontinued 
from the study .
xRecord the spherocylindrical refraction with best corrected distance visual acuity .
xCollect used test article(s) (worn or brought to  the visit) from the subject and discard 
them, unless otherwise stated in section 7.2.
xCollect all unused test article(s) from the subject .
xMake arrangements for subject care, if needed, due to their study participation
Additional subject smaybe enrolled if a subject discontinues from the study prematurely. 
In cases where a subject is lost to follow -up, every possible effort must  be made to contact the 
subject and determine the reason for disc ontinuation/withdrawal. The measures t aken to follow 
up must be documented including two written attemp ts and a certified letter (or equivalent) as 
the final attempt. 
CR-6420, v1.0
Page 40 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
9.PRE -STUDY AND CONCOMITANT INTERVENTION/MEDICATION  
Concomitant medications will be doc umented during screening and updated duri ng the study. 
Disallowed concomitant interventions for this study include ocular medications of any kind, 
or any systemic medications that would norm ally contraindicate contact lens wear ormay
otherwise compromise study endpoints .
9.1. Systemic Medications  
Certain systemic medications are known to have a higher likelihood to interfere with contact 
lens wear, chiefly by disrupting the tear film. 
A summary of disallowed systemic medications is shown in Table 4. Subjects with a history 
oftaking these medications will be allowed to enroll only if:
xThe medications have been taken on a continual, routine basis for at least 6 months ,
and
xThe subject has demonstrated successful contact lens wear during this time.
Or:
xThe s ubject was taking themedication on a temporary basis and ceased taking that 
medication at least 2 weeks prior to signing the informed consent (this is considered 
sufficient time for the medication to have left the body prior to enrollment) .
Subjects with a history of taking medications listed inTable 4on a long-term,routine basis for 
less than 6 months will not be allowed to participate in the study.
Table 4: Disallowed systemic medications
Class of Drug Common Indication(s) Common Examples
Estrogens (not
includingcontraceptive medication)Menopause, osteoporosis, vaginitis Vagifem, Estrace, Climara, 
Vivelle -Dot, Premarin, Minivelle, 
etc.
Anticholinergics Irritable bowel syndrome, 
Parkinson’s disease, peptic ulcer, 
cystitis, nasal congestion, cold symptoms, overactive bladder, COPDBentyl, Spiriva, Atrovent, 
Hyosyne, Levsin, Symax Fastab, Symax SL, Homax SL, Cogentin, Transderm Scop, etc.
Beta-blockers Hypertension, angina, heart attack, 
migraine, artrial fibrillation, andrenal cancer, essential tumor, glaucomaToprol XL, Lopressor, Tenormin, 
Propranolol, Timoptic, Trandate, Inderal LA, etc.
Psychotropics Antipsychotic (schizophrenia, 
mania), antidepression, Zoloft, Celexa, Prozac, Lexapro, 
Effexor, Cymbalta, Ativan, 
Xanax, Desyrel, Wellbutrin, etc.
CR-6420, v1.0
Page 41 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Class of Drug Common Indication(s) Common Examples
antiobsessive, antianxiety, mood 
stabilizer, stimulants (ADHD)
Vitamin A 
analogsCystic acne Isotretinoin
Examples of disallowed systemic antihistamines are given in Table 5.Subjects with a history 
of taking systemic a ntihistamines will be allowed to enroll only if:
xThey h ave t aken antihistamines continuously for at least 2 weeks ,and 
xTheyhavedemonstrated successful wear while taking the medication
Or:
xThey stopped taking the medication for at least 2 weeks prior to enrollment .
Table 5: Disallowed systemic antihistamines
Class of Drug Common Indication(s) Common Examples
Antihistamines Allergic rhinitis, sedation, hives, 
allergic conjunctivitis, skin allergy, itching, motion sicknessHydroxyzine, Promethagan, 
Phenadoz, Vistaril, Claritin, Zyrtec, Astepro, Astelin, Optivar, Allegra, Benedryl, etc.
10.DEVIATIONS FROM THE PROTOCOL  
Investigator will notify study sponsor upon identification of a protocol deviation. Protocol 
deviations must be reported to the sponsor within 24 hours after discovery of the protocol 
deviation. The Investigator will report deviations per IRB/IEC requirements. All deviations 
will be tracked ,and corrective actions implemented as appropriate. 
If it becomes necessary for the Investigator to implement a deviation in order to eliminate an 
immediate hazard to the trial subject, the Investigator may im plement the deviation 
immediately without notification to the spons or. Within 24 hours after the implemented 
deviation, the Investigator must notify and provi de the rationale to the Sponsor and, as 
required, the IEC/IRB. 
If the deviation potentially impa cts the safety of patient or chan ges the technical integrity of 
the study ,then it must be reported to IEC/IRB. This is a "Major Deviation". Deviations
that contradict the information contained in the Informed Consent/Assent forms will be
considered Majo r Deviations.
Minor deviations have no substantive effect on patien t safety or technical integrity of the 
study. They are often logistical in nature. 
Protocol waivers are prohibited .
CR-6420, v1.0
Page 42 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Table 6lists examples of deviation s that will constitute major and minor protocol deviation s
for this study. 
Table 6:Examples of major and minor protocol deviations
Deviation category Major deviation Minor deviation
Out-of-window visit Visit attended > 3 days out of 
visit window defined in study proceduresVisit attended ≤ 3 days out of 
visit window defined in 
study procedures
Unanswered PRO questions If questionnaire is not 
completed (i.e., all questions 
are unanswered) for any 
visit. Any individual PRO 
questions are unanswered 
(i.e., left blank) .
Insufficient wear of study 
lenses Subject does not wear study 
lenses for at least 8 hours on at least 5 days of a study lens wear period.
Subject wears their habitual 
lenses during any of the study lens wear periods.Subject does not wear study 
lenses for at least 1 hour prior to attending a follow-up visit.
In the case of a major protocol deviation, the decision of whether or not the subject will be 
excluded from the Per -Protocol analysis population will be made at the time of cohort 
review.
11.STUDY TERMINATION  
The occurrence of one or more Unanticipate d Serious Adverse Device Effect (USADE), or 
any SAE where the relationship to study agent cannot be rule d out, may result in stopping 
further dispensing of test article. In the event of a USADE or SAE, the Sponsor may unmask 
the treatment regimen for the subject(s) and w ill discuss this with the Investigator before any 
further subjects are enrolled.
The Spo nsor will determine when a study will be stopped. The Principal Investigator always 
has the discretion to initiate stopping the study  based on patient safety or if information 
indicates the study’s results are compromised.
JJVC reserves the right to termi nate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study  if an unreasonable risk is determined. The 
study can be terminated by the Principal Invest igator at the individual clinical site due to 
specific clinical observations, if in their opinion, after  a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.
CR-6420, v1.0
Page 43 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate  all adverse events. If it is 
determined that an adverse event presents an unreasonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible.
Should the study be terminated (either prematu rely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as  required by local regulatory requirements.
12.PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS  
A Product Quality Complaint (PQC) refers to an y written, electronic, or oral communication 
that alleges deficiencies relate d to the identity, quality, dura bility, reliability, safety, 
effectiveness or performance of test articles after they have been relea sed for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following a re not considered product quality complaints:
xSubject satisfaction inquiries reported via “Subjective Questionna ires” and “Patient 
Reported Outcomes (PRO) .”
xClinical test articles that are stored improperly or damaged after receipt at the 
investigational site .
xLens replacements that occur due to drops/fall -outs.
xDamage deemed by clinicians or clinical staff to be caused by handling by the user, 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where 
there is no deficiency alleged by the subject .
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be 
recorded in the EDC system, which will tr igger an automatic email notification to the 
appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use 
is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
Upon receipt of the E DC notification, the COM/CRA will contact the study site to collect 
additional information which will include: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor 
Awareness) .
xWho received the complaint .
xStudy number .
xClinical site information (contact name, site ID, telephone number) .
xLot number(s) .
xUnique Subject Identifier(s) .
xIndication of who first observed complaint (site personnel or subject) .
xOD/OS indication, along with whether the lens was inserted .
xAny related AE number if applicable .
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.) .
CR-6420, v1.0
Page 44 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xEye Care Provider objective (sli t lamp) findings if applicable .
xConfirmation of product availability for return  (and tracking information, if available), 
or rationale if product is not available for return 
Once a complaint is received, it will be assessed by the COM, CRA,  or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow section 13of this 
protocol. If the AE/SAE was potentially the result  of a product quality related deficiency, these 
procedures also applies and will be executed in parallel.  
In some ca ses, a PQC form may be generated in EDC by the site in error. In this event, the 
PQC forms will be marked “Intentionally Left Bla nk” or “ILB”.  Justification for ILB must be 
documented.
13.ADVERSE EVENTS  
13.1. Definitions and Classifications  
Adverse Event (AE) –An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to  the investigational medical device. ”
Note :This def inition includes events related to the investigational medical device or the 
comparator , and to the procedures involved .For users or other persons, this definition is 
restricted to events related to investigational medical devices .1
An AE includes any condition (including a pre -existing condition) that:
1.Was not present prior to the study, but app eared or reappeared following initiation of 
the study .
2.Was present prior to the study but worsened during the study. This would include any 
condition resulting from concomitant illnesse s, reactions to concomitant medications, 
or progression of disease states .
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event.
Serious Adverse Event (SAE) –An SAE is any adverse event thatled to any of the following :
xDeath
xSerious deterioration in the health of the subject th at resulted in any of the following:
xLife-threatening illness or injury
xPermanent or persistent impairment of a body structure or a body function
xHospitalization or prolongation of patient hospitalization
xMedical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function.
xChronic disease
CR-6420, v1.0
Page 45 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xFoetal distress, foetal death or a congenita l physical or mental impairment of birth 
defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best sp ectacle corrected visual acuity e quivalent to 2 acuity lines 
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epithelial Defect
xLimbal cell Damage leading to Conjunctivalization
Significant Adverse Events –are defined as events that are sympto matic and warrant 
discontinuation (temporary or permanent) of the contact lens wear
Diagnoses and conditions that are considered Oc ular Significant Adverse Events include, but 
not limited to the following:
xContact Lens Induced Peripheral Ulcer (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epithelial Arcuate Lesions (SEALs)
xAny Temporary Loss of > 2 Lines of BSCVA
xOther grade 3 or higher corneal findings, such as abrasions or edema
xNon-contact lens related corneal events -e.g. Epidemic Keratoconjunctivitis (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinuation > 2 weeks
Non-Significant Adverse Events –are defined as those events that are usually asymptomatic 
and usually do not warrant discon tinuation of contact lens wear but  may cause a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure .
Diagnoses and conditions that are considered Ocular Non -Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact Lens Papillary Conjunctivitis (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
CR-6420, v1.0
Page 46 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xBlepharitis
xMeibomianitis
xContact Dermatitis
xLocalized A llergic Reactions
xAny corneal event not explicitly defined as serious or significant adverse event, which 
necessitates temporary lens discontinuation < 2 weeks
Adverse Device Effect (ADE) –An ADE is an “adverse event related to the use of an 
investigatio nal medical device. ”
Note1:This definition includes adverse events re sulting from insufficient or inadequate 
instructions for use, deployment, implanta tion, installation, or operation, or any malfunction 
of the investigational medical device.
Note2:This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device.1
Unanticipated Adverse Device Effect (UADE) –A UADE is a ny serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, the test 
article, if that effect, problem, or death was not previ ously identified in nature, severity, or 
degree of incidence in the investigational p lan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem asso ciated with the test article that rela tes to the rights, 
safety and welfare of subjects.
13.2. Assessing Adverse Events  
In conjunction with the medical monitor, the Invest igator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization will include:
xSeriousness/Classifications (see definition in section 13.1).
xCausality or Relatedness –i.e. the relationship between the test article, st udy treatment 
or study procedures and the adverse event (not related ,unlikely related ,possibly
related ,orrelated -see definition in section 13.2.1 ).
xAdverse Event Severity –Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild ,moderate ,orsevere -see definition in section 
13.2.2 ).
xOutcome –not recovered or not resolved ,recovering or resolving ,recovered or 
resolved with sequelae ,recovered or resolved ,death related to adverse event , or
unknown .
xActions Taken –none ,temporarily discontinued ,permanently discontinued , orother .
13.2.1. Causality Assessment  
Causality Assessment –A determination of the r elationship between an adverse event and the 
test article. The test article relationship for each  adverse event should be determined by the 
investigator using these explanations:
xNot Related -An adverse event that is not related to the use of the test arti cle, study 
treatment or study procedures .
CR-6420, v1.0
Page 47 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xUnlikely Related –An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomi tant disease(s), or the relationship of time 
suggests that a causal relationship is not li kely.
xPossibly Related –An adverse event that might be due  to the use of the test article, or 
to the study treatment or study procedures. An  alternative explanation, e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is 
reasonable. Therefore, the causal relationship cannot be excluded .
xRelated –An adverse event that is listed as a po ssible adverse effect (device) or adverse 
reaction (drug) and cannot be reasonably exp lained by an alternative explanation, e.g. 
concomitant treatment of concomitant dise ase(s). The relationship in time is very 
suggestive, e.g. it is confirmed by de -challenge and re -challenge .
13.2.2. Severity Assessment  
Severity Assessment –A qualitative assessment of the degree of intensity of an adverse ev ent 
as determined by the Investigator or reported to  him/her by the subject. The assessment of 
severity is made irrespective of test article, st udy treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to t he following scale:
xMild –Event is noticeable to the subject but is  easily tolerated and does not interfere 
with the subject’s daily activities .
xModerate –Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s da ily activities .
xSevere –Event is intolerable, necessitates additi onal therapy or alteration of therapy 
and interferes with the subject’s daily activities .
13.3. Documentation and Follow -Up of Adverse Events  
The recording and documenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the condition deteriora tes at any time during the study 
it will be recorded and reported as an AE. Unto ward medical events reported after the subject’s 
exit from the study will be recorded as adve rse events at the discretion of the Investigato r.
Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs andcomplete the Adverse Event eCRF.  
Complete descriptions of all adverse events must be available in the subject record. Al l
Adverse Events including local and systemic re actions not meeting the criteria for “serious 
adverse events” shall be capture d on the appropriate case report form or electronic data system. 
All adverse events occurring while the subject is enrolled in the study must be documented 
appropriately regardless of relationship.  
It is the Investigator’s responsibility to maintain  documentation of each reported adverse event. 
All adverse events will be followed in acco rdance with applicable licensing requirement s. Such 
documentation will include the following:
xAdverse event (diagnosis not symptom) .
CR-6420, v1.0
Page 48 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xDrawings or photographs (where appropriate) that detail the finding (e.g., size, 
location, and depth, etc.) .
xDate the clinical site was notified .
xDate and time of onset .
xDate and time of resolution .
xAdverse event classification, severity, and relationship to test articles, as applicable .
xTreatment regimen instituted (where appropriate) , including concomitant medications 
prescribed, in accordance with applicable lice nsing requirements .
xAny referral to another health care provider if needed .
xOutcome, ocular damage (if any) .
xLikely etiology .
xBest corrected visual acuity at the disc overy of the event and upon conclusion of the 
event , if the AE is related to the visual sy stem .
Upon discovery of an AE that is deemed ‘possibly related ’or ‘related ’to the test article or 
study procedures (whether related to the visual system or not), a nAE review form 
must be completed .Additional dated and initialed entries should be made atfollow -up 
evaluations .Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he /she will complete the Corneal Infiltrate Assessment 
eCRF. Where necessary , a culture of the corneal lesion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be docume nted to allow an assessment of the duration 
of the event at each level of in tensity to be performed. Adve rse events characterized as 
intermittent require documentation of the onset and duration of each episode. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.
Subjects who present with an adverse event shall be followed by the Investigator, within 
licensure, until all signs and symptoms have returned to pre -treatment status, stabilized, or 
been satisfactorily r esolved. If further treatment beyond licen sure is required, the patient will 
be referred to the appropriate health care provi der. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in t he study. If 
a subject is discontinued from the study, it w ill be the responsibility of the Investigator to 
record the reason for discontinuation. The Investig ator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse 
events related to the test article, study treatment or study procedures, as of the final study visit 
date, should be followed to resolution of the adverse event or until referral to an appropriate 
health care provider, as reco mmended by the Investigator. Non -ocular adverse events that are 
not related to the test article, study treatmen t, or study procedures may be recorded as 
“ongoing” without further follow -up.
CR-6420, v1.0
Page 49 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e -mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for any non -significant adverse event. In addition, 
a written repor t will be submitted by the Principal In vestigator to the IEC/IRB according to 
their requirements ( section 13.4.2 ). The report will comment whether the adverse event was 
considered to be related to the test article, study treatment or study procedures.
13.4.1. Reporting Adverse Events to Sponsor  
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e -mail or telephone, but no later than 24 hours 
following discovery of the event. The Invest igator is obligated to pursue and obtain 
information requested by the Sp onsor in addition to that information reported on the eCRF. All 
subjects experiencing a serious/si gnificant adverse event must be  followed up and all outcomes 
must be reported.
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject  received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.
In the event of a serious/significant adverse event, the Investigator must:
xNotify the Sponsor immediately .
xObtain and maintain in the subject’s records all pertinent medical information and 
medical judgment for colleagues who a ssisted in the treatment and follow -up of the 
subject .
xProvide the Sponsor with a complete case history whi ch includes a statement as to 
whether the event was or was not related to the use of the test article .
xNotify the IEC/IRB as required by the IEC/IRB reporting procedure according to 
national regulations .
Unanticipated (Serious) Adverse Device Effect (UADE )
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than 24 hours after the Investigator first learns of the effect. This report is in addition to the 
immediate notification mentioned above.
The Sponsor must conduct an evaluation of the UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within 10 working days after 
the Spon sor first receives notification of the effect.
Non-Serious Adverse Events
All non -serious adverse events, including non -serious adverse device effects, will be reported 
to the sponsor by the Investigator no later than 2 days from discovery.
CR-6420, v1.0
Page 50 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4.2. Reporting Adve rse Events to the Responsible IEC/IRB and Health Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth 
by their Approving IEC/IRB. Each clinical site will  refer to and follow any guidelines set forth 
by their local governing Health Authorities.
The Sponsor will report applicable Adverse Events to the local health authorities according the 
written guidelines, i ncluding reporting timelines. 
13.5. Event of Special Interest  
None.
13.6. Reporting of Pregnancy  
Subjects reporting pregnancy (by self -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregnant participa nts and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact lens or solution relate d studies for safety concerns, but due to 
general concerns relating to pre gnancy and contact lens use. Sp ecifically, pregnant women are 
discontinued due to fluctuations in  refractive error and/or visual  acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.
14.STATISTICAL METHODS  
14.1. General Considerations  
Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A 
general description of the statistical methods to be implemented in this clinical trial is outlined 
below.
All data summaries and statistical a nalyses will be performed using the SAS software Version 
9.4 or higher (SAS Institute, Cary, NC).  Throughout the analysis of data, the results for each 
subject/eye will be used when available for summarization and statistical analysis.
Summary tables (d escriptive statistics and/or frequency tab les) will be provided for all baseline 
variables, efficacy variables and safety variable s as appropriate. Continuous variables will be 
summarized with descriptive statistics  (n, mean, standard deviation (SD), media n, minimum 
and maximum). Frequency count an d percentage of subjects or eyes within each category will 
be provided for categorical data.
14.2. Sample Size Justification  
Approximately 66 subjects will be enrolled in this study to attain a minimum of 60 completed 
subjects.  All endpoints will be summarized using descriptive statistics only; no formal 
hypothesis testing will be conducted.  This is a descriptive study to evaluate the clinical 
performance of ACUVUE OASYS® 1 -Day for Astigmatism contact lenses produced o n a 
CR-6420, v1.0
Page 51 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
recently qualified manufacturing line.  Sample size is not based on the empirical power 
analysis.  The data collected for this study may be used in future study design if applicable.
14.3. Analysis Populations  
Safety Population:
All subjects who are administered any test article excludi ng subjects who drop out prior to 
administering any test article. At lea st one observation should be recorded.
Per-Protocol Population: 
All subjects who successfully complete al l visits and do not substantially deviat e from the 
protocol as determined by the trial cohort revi ew committee prior to database hard lock. 
Justification for the exclusion of subjec ts with protocol deviations from the Per-Protocol 
Population set will be documented in a memo to file.
Intent -to-Treat (ITT) Population:
All randomized subjects regardless of actual tr eatment and subsequent withdrawal from the 
study or deviation from the protocol. At least one observation should be recorded.
14.4. Level of Statistical Significance  
No inferential statistics are planned to be performed in this  study; hence, the level of statistical 
significance is not a concern. If statistical analysis is conducted, an overall type I error rate of 
5% will be used.
14.5. Primary Analysis  
Descriptive summary tables of the following endpoints will be provided without formal 
hypothesis test.
xCLUE comfort, vision and handling at fi tting and following 7(±2) days of wear 
xHigh luminance, high contrast (HLHC) logMAR visual acuity measured using ETDRS 
acuity charts at follow -up 
xLens orientation at 1 and 3 minutes following insertion 
Mean and standard deviation of settled lens ori entation, as calculated from repeated measure s
of signed lens orientation at fitting and follow -up visits.
14.6. Secondary Analysis  
Not applicable.  
14.7. Other Exploratory Analys is 
Not applicable.  
14.8. Interim Analysis  
Not applicable.
CR-6420, v1.0
Page 52 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.9. Procedure for Handling Missing Data and Drop -Outs  
Missing or spurious values wi ll not be imputed. The count of mi ssing values will be included 
in the summary tables and listings. 
14.10. Procedure for Reporting Deviations from Statistical Plan  
The analysis will be conducted according to th at specified in above sections. There are no 
known r easons for which it is planned to deviate from these analysis methods. If for any reason 
a change is made, the change will be documented in the study report along with a justification 
for the change.
15.DATA HANDLING AND RECORD KEEPING/ARCHIVING  
15.1. Electronic Ca se Report Form/Data Collection  
The data for this study will be capture d on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data originator will enter study dat a into the eCRFs 
using the EDC system. Data collected on equip ment that is not captured in EDC will be 
formatted to the specification of the JJVC database manager and sent to JJVC for analysis. 
No e xternal datasources will be included in this study .
The clinical data will be recorded on dedicated e CRFs specifically designed to match the study 
procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed  for accuracy and completeness and signed by the 
Investigator. The sponsor or sponsor’s representative s will be authorized to gain access to the 
subject recordation for the purposes of monitoring and auditing the study. 
Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and 
complete data collection. Data will be transmitte d from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit tr ail on electronic media in PDF format for all of 
the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant with ISO14155:2011 .1
15.2. Subject Record  
At a minimum, subject record should be available for the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
CR-6420, v1.0
Page 53 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xvisit dates
xresults of safety and efficacy parameters as required by the protocol
xa record of all adverse events
xfollow -up of adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study com pletion
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is consi dered to be the source record.
Adverse event notes must be reviewed and initialed by the Investigator.
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by the Sponsor.
16.DATA MANAGEMENT  
16.1. Access to Source Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents. Should the 
clinical site be contacted for an audit by an IEC/IRB or re gulatory authority, JJVC must be 
contacted and notified in writing within 24 hours.
16.2. Confidentiality of Information  
Information concerning the investigational product and patent application processes, scientific 
data or other pertinent information is confid ential and remains the property of JJVC. The 
Investigator may use this information for the purpo ses of the study only. It is understood by 
the Investigator that JJVC will use information deve loped in this clinical study in connection 
with the development o f the investigational product and ther efore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clinical study, th e Investigator understands that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor.
16.3. Data Quality Assurance  
Steps will be taken to ensure the accuracy a nd reliability of data, include the selection of 
qualified investigators and appropri ate clinical sites and review of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub -
Investigators and clinical site personnel ar e familiar with the protocol and all study -specific 
procedures a nd have appropriate knowledge of the study article.
CR-6420, v1.0
Page 54 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Training on case report form completion will be provided to clinical site personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during t he conduct of the study, during monitori ng visits, and after transmission to 
data management. Any data discrepancies will be  resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pe rtaining to the conduct 
of clinical trials. The clinical sites will provide direct access to study -related source 
data/documents and reports for the purpo se of monitoring and auditing by JJVC and for 
inspection by local and regulatory authorities.
16.4. Data Monitoring Committee  (DMC)  
Not applicable for this study. 
17.CLINICAL MONITORING  
The study monitors will maintain close contact with the Principal Investigator and the 
Investigator’s designated clinical site personnel. The monitor’s responsibilities will include:
xEnsuring that the investigation is bei ng conducted according to the protocol, any 
subsequent versions , and regulatory requirements are maintained .
xEnsu ring the rights and wellbeing of subjects are protected .
xEnsuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site personnel .
xEnsuring that protocol deviations are documen ted with corrective action plans, as 
applicable .
xEnsuring that the clinical site has sufficient test article and supplies .
xClarifying questions regarding the study .
xResolving study issues or problems that may arise .
xReviewing of study records and source documentation ve rification in accordance with
the monitoring plan .
18.ETHICAL AND REGULATORY ASPECTS  
18.1. Study -Specific Design Considerations  
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new information that may  affect their decision to continue 
participation. Subjects will be to ld that their consent to particip ate in the study is voluntary and 
may be withdrawn at any time with no re ason given and without penalty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if t he fully able to 
understand the risks, benefits, and potential adverse events of the study andprovide their 
consent voluntarily .
Page 55 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
18.2. Investigator Responsibility  
The Principal Investigator is responsible for ensuring that the clinical study is performed in 
accordance with the signed agreement, the investigational plan, section 4 of the ICH E6 (R2)
guidelines on Good Clinical Practice (GCP) ,2and applicable regulatory requirements. GCP is 
an international ethical and scientific quality  standard for designing, conducting, recording, 
and reporting s tudies that involve the participation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well -being of study subjects are 
protected, consistent with the principles of the Declaration of Helsinki 64th WMA  General 
Assembly 20133 and that the clinical study data are cr edible. The Investigator must maintain 
clinical study files in accordance with section 8 of the ICH E6 (R2) guidelines on Good Clinical 
Practice (GCP) ,2and applicable regulatory requirements.
18.3. Independent Ethics Committee or Institutional R eview Board (IEC/IRB)  
Before the start of the study, the Investigator (o r Sponsor when applicable) will provide the 
IEC/IRB with current and complete copies of  the following documents (where applicable):
xFinal protocol .
xSponsor -approved informed consent fo rm (and any other written materials to be 
provided to the subjects)
xInvestigator’s Brochure (or equivalent information) .
xSponsor -approved subject recruitment materials .
xInformation on compensation for study -related injuries or payment to subjects for 
participation in the study .
xInvestigator’s curriculum vitae, clinical licenses, or equivalent information (unless not 
required, as documented by IEC/IRB) .
xInformation regarding funding, name of the S ponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for subjects .
xAny other documents that the IEC/IRB requests to fulfill its obligation .
This study will be undertaken only after IEC/ IRB has given full approval of the final protocol,
the informed consent form, applicable recrui ting materials, and subject compensation 
programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly identify the documents being approved.
During the study, the Investigator (or Sponsor when applica ble) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:
xProtocol revisions
xRevision(s) to informed consen t form and any other written materials to be provided to 
subjects
xIf applicable, new or revised subject recruitment materials approved by the Sponsor
xRevisions to compensation for study -related injuries or payment to subjects for 
participation in the study
xInvestigator’s Brochure revisions
xSummaries of the status of the study  (at least annually or at inter vals stipulated in 
guidelines of the IEC/IRB)
Page 56 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xReports of adverse events that are serious, unanticipated, and asso ciated with the test 
articles, according to the IRB’s requirements
xNew information that may adversely affe ct the safety of the subjects or the conduct of 
the study
xMajor protocol deviations as required by the IEC/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Investigator is res ponsible for the study at the clinical site
xAny other requirements of the IEC/ IRB
For protocol revisions that increase subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to  the IEC/IRB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Do cumentation of this notificati on must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consent  
Each subject or their representative, must give written consent according to local requirements 
after the nature of the study has been fully explained. The consent form must be signed before 
performance of any study -related activity. The consent form that is used must be approved by 
both the Sponsor and by the reviewing IEC/IRB. The informed consent is in accordance with 
principles that origina ted in the Declaration of Helsinki,3current ICH GCP2andISO 141551
guidelines, applicable regulatory requirements, and Sponsor Policy.
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort it may entail. Subjects will be informed 
that their participation is voluntary and that th ey may withdraw consent to participate at any 
time. 
The subject will be given sufficient time to re ad the informed consent form and the opportunity 
to ask questions. After this e xplanation and before entry into the study, consent should be 
appropriately recorded by means of the subject 's dated signature. After having obtained the 
consent, a copy of the informed consent form must be given to the subject.
18.5. Privacy of Personal Data  
The collection, processing and disclosure of pe rsonal data and medical information related to 
the Study Subject, and personal data related to  Principal Investigator and any clinical site 
personnel (e.g., name, clinic address and phone number, curriculum vit ae) is subject to 
compliance with the Health Information Portability a nd Accountability Act (HIPAA)5and 
Page 57 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
other applicable personal data protection an d security laws and regulations. Appropriate 
measures will be employed to safeguard thes e data, to maintain the confidentiality of the 
person’s related health and medical information, to properly inform the concerned persons 
about the collection and proces sing of their personal data, to grant them reasonable access to 
their personal data and to prevent access by unauthorized persons.
All information obtained during the course of the invest igation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by Investigators, 
monitors, Sponsor’s personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subjec t concerned, with the exception of Sponsor 
personne l (monitor, auditor), IEC/IRB and regulatory organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs 
and subject records.
The collection and processing of personal data from su bjects enrolled in this study will be 
limited to those data that are necessary to invest igate the efficacy, safety, quality, and utility of 
the investigational product(s) used in this study.
These data must be collected a nd processed with adequate precaut ions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations.
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully .
xcollected for specified, explicit, and legitimate purposes and not further processed in a 
way incompatible with these purposes .
xadequate, relevant, and not excessive in relation to said purposes .
xaccurate and, where necessary, kept current .
Explicit consent for the processing of personal data will be obt ained from the participating 
subject before collection of data. Such consent should also addre ss the transfer of the data to 
other entities and to other countries.
The subject has the right to request through th e Investigator access to his personal data a nd the 
right to request rectificati on of any data that are not correc t or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations.
Appropriate technical and organizational meas ures to protect the personal data against 
unauthorized disclosures or access, accidental or  unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor personnel whose res ponsibilities require access to 
personal data agree to keep the identity of study subjects confidential .
19.STUDY RECORD RETENTION  
In compliance with the ICH GCP guidelines ,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the data co llected from each subject, as well as all 
Page 58 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
study documents as specified in ICH GCP2and all study documents as specified by the 
applicable regulatory requirement(s). The Investigator/Institution will take measures to prevent 
accidental or premature destruction of these documents.
Essential documents must be retained until at least two ( 2)years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications  in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical developmen t of the investigational product. These 
documents will be retained for a longer period if required by the applicable regulatory 
requiremen ts or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained.
If the responsible Investigator retires, relocates, or for other reasons withdraws fr om the 
responsibility of keeping the study records, custo dy must be transferred to a person who will 
accept the responsibility. The Sponsor must be not ified in writing of th e name and address of 
the new custodian.  Under no circumstance shall the Investigat or relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator mu st permit access to such reports.
If the Investigator has a question regarding re tention of study records, he/she should contact 
JJVC.
20.FINANCIAL CONSIDERATIONS  
Remuneration for study services and expenses will be set forth in detail in the Clinical Resear ch 
Agreement. The Research Agree ment will be signed by the Principal Investigator and a JJVC 
management representative prior to study initiation.
JJVC reserves the right to withhold remuneration for costs associated with protocol violations 
such as:
xConti nuing an ineligible subject in the study .
xScheduling a study visit outside the subject’s acceptable visit range .
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:
xQuery resolution .
xCase Report Form signature .
xCompletion of any follow -up action items .
21.PUBLICATION  
There is no plan to externally publish this outcome of this investigation.
Page 59 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
22.REFERENCES  
1.ISO 14155:2011: Clinical Investigation of Medical Devices for Human Subjects —
Good Clinical Practice. Available at: https://www.iso.org/standard/45557.html
2.International Council for Harmonization Good Clinical Practice E6 (R2) (ICH GCP). 
Available at: https://www.ich.org/page/efficacy -guidelines
3.Declaration of Helsinki -Ethical principles for Medical Research Involving Human 
Subjects. Available at: https://www.wma.net/policies -post/wma -declaration -of-
helsinki -ethical -principles -for-medical -research -involving -human -subjects/
4.United States (US) Code of Federal Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collecti onCfr.action?collectionCode=CFR
5.Health Information Portability and Accountabilit yAct (HIPAA). Available at: 
https://www.hhs.gov/hipaa/for -professionals/privacy/index.html
 
Page 60 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
 
Page 61 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
Page 62 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
Page 63 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
Page 64 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
Page 65 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
Page 66 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
Page 67 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
Page 68 of 160
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
Page 69 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE   
A Patient Instruction Guide (PIG) will be provided separately. 
Page 70 of 160
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
ACUVUE OASYS® BRAND CONTACT LENSES 1 -DAY WITH HYDRALUXETM
TECHNOLOGY FOR ASTIGMATISM
Page 71 of 160
IMPORTANT:  Please read carefully and keep this 
information for future use.
This Package Insert and Fitting Guide is intended for the 
Eye Care Professional, but should be made available to 
patients upon request. 
The Eye Care Professional should provide the patient 
with the appropriate instructions that pertain to the 
patient’s prescribed lenses. Copies are available for 
download at www.acuvue.com.
senoﬁ  lcon A Soft (hydrophilic) Contact Lenses
Visibility Tinted with UV Blocker
for Daily Disposable Wear
CAUTION: U.S. Federal law restricts this device to 
sale by or on the order of a licensed practitioner.ACUVUE OASYS® Brand Contact Lenses 1-Day 
with HydraLuxeTM Technology
ACUVUE OASYS® Brand Contact Lenses 1-Day 
with HydraLuxeTM Technology for ASTIGMATISM
 
Page 72 of 160
SYMBOLS KEY
The following symbols may appear on the label or carton:
Date of ManufactureManufactured by or inConsult Instructions for Use
CAUTION: U.S. Federal law restricts this device 
to sale by or on the order of a licensed practitionerUse By Date (expiration date)
Diameter DIA
Base Curve BC
Diopter (lens power) DBatch Code LOT
Sterile Using Steam or Dry Heat STERILE
UV-Blocking
Fee Paid for Waste ManagementQuality System Certification Symbol
123Lens Orientation Correct
123Lens Orientation Incorrect (Lens Inside Out) CYL
AXISCylinder
AxisSingle-Use
Page 73 of 160
DESCRIPTION
ACUVUE OASYS® Brand Contact Lenses 1-Day and ACUVUE OASYS® 
Brand Contact Lenses 1-Day for ASTIGMATISM are soft (hydrophilic) 
contact lenses made with HydraLuxe™ Technology. They are available as spherical or toric lenses respectively. 
These lenses are made of a silicone hydrogel material containing an internal 
wetting agent, visibility tint, and UV absorbing monomer and are tinted blue using Reactive Blue Dye #4 to make the lenses more visible for handling.
A benzotriazole UV absorbing monomer is used to block UV radiation. The 
transmittance characteristics for these lenses are less than 1% in the UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm 
for the entire power range.
Lens Properties:
The physical/optical properties of the lens are:
• Speciﬁ  c Gravity (calculated): 0.98 - 1.12
• Refractive Index: 1.42
• Light Transmission: 85% minimum• Surface Character: Hydrophilic• Water Content: 38%
• Oxygen Permeability:
VALUE METHOD
122 x 10
-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, non-
edge corrected)
103 x 10-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, edge corrected)
Lens Parameters:
• Diameter Range: 12.0 mm to 15.0 mm
• Center Thickness: varies with power
• Base Curve Range: 7.85 mm to 10.00 mm
• Spherical Power Range: -20.00D to +20.00D
• Cylinder Power Range: .25D to -10.00D
• Axis Range: 2.5° to 180°Page 74 of 160
AVAILABLE LENS PARAMETERS
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology are 
hemispherical shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.085 mm to 0.221 mm (varies with power)
Base Curve: 8.5 mm, 9.0 mm
Powers: -0.50D to -6.00D (in 0.25D increments)
-6.50D to -12.00D (in 0.50D increments)+0.50D to +6.00D (in 0.25D increments)+6.50D to +8.00D (in 0.50D increments)
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology for 
ASTIGMATISM  are hemitoric shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.075 mm to 0.172 mm (varies with power)
Base Curve: 8.5 mm
Powers: +0.00D to -6.00D (in 0.25D increments)
Cylinders: -0.75D, -1.25D, -1.75D, -2.25D*Axis: 10° to 180° in 10° increments
*-2.25D cylinder is availble in 10°, 20°, 70°, 80°, 90°, 100°, 110°, 
160°, 170°, 180° axes only.
+0.25D to +4.00D (in 0.25D increments)
-6.50D to -9.00D (in 0.50D increments)Cylinders: -0.75D, -1.25D, -1.75DAxis: 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 
170°, 180°
Page 75 of 160
TRANSMITTANCE CURVES
ACUVUE OASYS® 1-Day with HydraLuxe™ Technology  (senoﬁ  lcon A) 
Visibility Tinted with UV Blocker vs. 24 yr. old human cornea and 25 yr. old 
human crystalline lens. 
……. ACUVUE OASYS®  
1-Day with HydraLuxe™ Technology (senoﬁ  lcon A)*
_____ 24 YR. OLD HUMAN CORNEA
1
- - - - - 25 YR. OLD HUMAN CRYSTALLINE LENS
2
* The data was obtained from measurements taken through the central 3-5 mm portion for 
the thinnest marketed lens (-9.00D lens, 0.075 mm center thickness).
1Lerman, S., Radiant Energy and the Eye, MacMillan, New York, 1980, p. 58, ﬁ  gure 2-21
2Waxler, M., Hitchins, V.M., Optical Radiation and Visual Health, CRC Press, Boca Raton, Florida, 
1986, p. 19, ﬁ  gure 5 
WARNING: UV absorbing contact lenses are NOT substitutes for 
protective UV absorbing eyewear, such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.
ACTIONS
In its hydrated state, the contact lens, when placed on the cornea, acts as a refracting medium to focus light rays onto the retina.
The transmittance characteristics for these lenses are less than 1% in the 
UVB range of 280 nm to 315 nm than 10% in the UVA range of 316 nm to 380 nm for the entire power range.
P
NOTE:  Long-term exposure to UV radiation is one of the risk 
factors associated with cataracts.  Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities).  UV-Blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-Blocking contact lenses reduces the risk of developing cataracts or other eye disorders. The Eye Care Professional should be consulted for more information.
INDICATIONS (USES)
ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxe™ 
Technology are indicated for daily disposable wear for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who may have 1.00D or less of astigmatism.
ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxe™ Tech-
nology for ASTIGMATISM are indicated for daily disposable wear for the 
optical correction of refractive ametropia (myopia and hyperopia) in phakic 
or aphakic persons with non-diseased eyes who may have 0.50D to 3.00D of astigmatism.
These lenses contain a UV Blocker to help protect against transmission of 
harmful UV radiation to the cornea and into the eye.
CONTRAINDICATIONS (REASONS NOT TO USE) 
DO NOT USE these contact lenses when any of the following conditions exist:
• Acute or subacute inﬂ  ammation or infection of the anterior chamber 
of the eye.
• Any eye disease, injury or abnormality that affects the cornea, 
conjunctiva, or eyelids.
• Severe insufﬁ  ciency of  (dry eye).
Page 77 of 160
• Corneal hypoesthesia (reduced corneal sensitivity).
• Any systemic disease that may affect the eye or be exaggerated by 
wearing contact lenses.
• Allergic reactions of ocular surfaces or adnexa that may be induced 
or exaggerated by wearing contact lenses or use of contact lens 
solutions.
• Ocular irritation due to allergic reactions which may be caused by 
use of contact lens solutions (i.e., rewetting drops) that contain chemicals or preservatives (such as mercury, Thimerosal, etc.) to which some people may develop an allergic response.
• Any active corneal infection (bacterial, fungal, protozoal, or viral).
• If eyes become red or irritated.
WARNINGS
Patients should be advised of the following warnings pertaining to 
contact lens wear:
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP 
RAPIDLY AND LEAD TO LOSS OF VISION; IF THE PATIENT EXPE-RIENCES:
• Eye Discomfort,
• Excessive Tearing,• Vision Changes,• Loss of Vision,• Eye Redness,• Or Other Eye Problems, 
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE-
MOVE THE LENSES AND PROMPTLY CONTACT THE EYE CARE PROFESSIONAL.
• When prescribed for daily wear, patients should be instructed not 
to wear lenses while sleeping. Clinical studies have shown that 
the risk of serious  is increased when lenses are worn overnight, and that the risk of ulcerative keratitis is greater for 
extended wear contact lens users than for daily wear users.3
• Studies have shown that contact lens wearers who are smokers 
have a higher incidence of adverse reactions than nonsmokers.
• Problems with contact lenses or lens care products could result in 
serious injury to the eye. Patients should be cautioned that proper 
use and care of contact lenses and lens care products are essential for the safe use of these products.
• The overall risk of ulcerative keratitis may be reduced by carefully 
following directions for lens care.
3 New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773-783
Speciﬁ  c Instructions for Use and Warnings:
• Water Activity
Instructions for Use
Do not expose contact lenses to water while wearing them.WARNING:
Water can harbor microorganisms that can lead to severe infection, vision loss or blindness. If lenses have been submersed in water when participating in water sports or swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard them and replace them with a new pair. The Eye Care Professional should be consulted for recommendations regarding wearing lenses during any activity involving water.
PRECAUTIONS
Special Precautions for Eye Care Professionals:
• Due to the small number of patients enrolled in clinical investiga-
tion of lenses, all refractive powers, design conﬁ  gurations, or lens parameters available in the lens material are not evaluated in signif-icant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, wettability, central and peripheral thickness, and  diameter.
• The potential impact of these factors on the patient’s ocular health 
should be carefully weighed against the patient’s need for refractive 
correction; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by the prescribing Eye Care Professional.
• Patients who wear these lenses to correct presbyopia using mono-
vision may not achieve the best corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
• Fluorescein, a yellow dye, should not be used while the lenses are 
on the eyes. The lenses absorb this dye and become discolored. Whenever ﬂ  uorescein is used in eyes, the eyes should be ﬂ  ushed with a sterile saline solution that is recommended for in-eye use.
• Eye Care Professionals should instruct the patient to remove the 
lenses immediately if the eyes become red or irritated. 
Eye Care Professionals should carefully instruct patients about the following care regimen and safety precautions.
Handling Precautions:
• Before leaving the Eye Care Professional’s ofﬁ  ce, the patient should 
be able to promptly remove the lenses or should have someone 
else available who can remove the lenses for him or her. 
• DO NOT use if the sterile blister package is opened or damaged. 
• Always wash and rinse hands before handling lenses. Do not get 
cosmetics, lotions, soaps, creams, deodorants, or sprays in the 
eyes or on the lenses. It is best to put on lenses before putting on makeup. Water-based cosmetics are less likely to damage lenses than oil-based products. 
• DO NOT touch contact lenses with the ﬁ  ngers or hands if the 
hands are not free of foreign materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to the eye.
• Carefully follow the handli n, removal, and wearing 
instructions in the “Patient Instruction Guide” for the prescribed 
Page 80 of 160
wearing schedule and those prescribed by the Eye Care 
Professional.
• Always handle lenses carefully and avoid dropping them.
• Never use tweezers or other tools to remove lenses from the lens 
container unless speciﬁ  cally indicated for that use. Slide the lens up 
the side of the bowl until it is free of the container. 
• Do not touch the lens with ﬁ  ngernails. 
Lens Wearing Precautions:
• If the lens sticks (stops moving) on the eye, follow the recom-
mended directions in “Care for a Sticking (Non-Moving) Lens." The lens should move freely on the eye for the continued health of the eye. If non-movement of the lens continues, the patient should be instructed to immediately consult his or her Eye Care Professional.
• Never wear lenses beyond the period recommended by the Eye 
Care Professional.
• The patient should be advised to never allow anyone else to wear 
their lenses. They have been prescribed to ﬁ  t their eyes and to correct their vision to the degree necessary. Sharing lenses greatly increases the chance of eye infections.
• If aerosol products, such as hair spray, are used while wearing 
lenses, exercise caution and keep eyes closed until the spray has settled.
• Avoid all harmful or irritating vapors and fumes while wearing 
lenses. 
• Always discard lenses worn as prescribed by the Eye Care 
Professional. 
Lens Care Precautions:  
• The patient should be informed that no cleaning or disinfection is 
needed when lenses are worn for daily disposable wear.  Patients should always dispose of lenses when removed and have spare lenses or spectacles available.
Page 81 of 160JJVC CONFIDENTIAL
Other Topics to Discuss with Patients:
• Always contact the Eye Care Professional before using any medi-
cine in the eyes. 
• Certain medications, such as antihistamines, decongestants, 
diuretics, muscle relaxants, tranquilizers, and those for motion 
sickness may cause dryness of the eye, increased lens awareness, or blurred vision. Should such conditions exist, proper remedial measures should be prescribed. Depending on the severity, this could include the use of lubricating drops that are indicated for use with soft contact lenses or the temporary discontinuance of contact lens wear while such medication is being used. 
• Oral contraceptive users could develop visual changes or changes 
in lens tolerance when using contact lenses. Patients should be cautioned accordingly. 
• As with any contact lens, follow-up visits are necessary to assure 
the continuing health of the patient’s eyes. The patient should be instructed as to a recommended follow-up schedule. 
Who Should Know That the Patient is Wearing Contact Lenses?
• Patients should inform all doctors (Health Care Professionals) about 
being a contact lens wearer. 
• Patients should always inform their employer of being a contact 
lens wearer. Some jobs may require use of eye protection equip-ment or may require that the patient not wear contact lenses. 
ADVERSE REACTIONS
The patient should be informed that the following problems may occur when wearing contact lenses:
• The eye may burn, sting, and/or itch.
• There may be less comfort than when the lens was ﬁ  rst placed on 
the eye.
• There may be a feeling of something in the eye (foreign body, 
scratched area).
• There may be the potential for some temporary impairment due to CR-6420, v1.0
Page 82 of 160JJVC CONFIDENTIAL
peripheral inﬁ  ltrates, peripheral corneal ulcers, or corneal erosion. 
There may be the potential for other physiological observations, such as local or generalized edema, corneal neovascularization, corneal staining, injection, tarsal abnormalities, iritis, and conjuncti-vitis; some of which are clinically acceptable in low amounts.
• There may be excessive watering, unusual eye secretions, or 
redness of the eye.
• Poor visual acuity, blurred vision, rainbows, or halos around 
objects, photophobia, or dry eyes may also occur if the lenses are worn continuously or for too long a time.
The patient should be instructed to conduct a simple 3-part self-examina-tion at least once a day. They should ask themselves:
• How do the lenses feel on my eyes?
• How do my eyes look?• Have I noticed a change in my vision? 
If the patient reports any problems, he or she should be instructed to 
IMMEDIATELY REMOVE THE LENS. If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the eye.
If after inserting the new lens, the problem continues, the patient should be 
directed to IMMEDIATELY REMOVE THE LENS AND CONTACT HIS OR HER EYE CARE PROFESSIONAL.
The patient should be instructed NOT to use a new lens as self-treatment 
for the problem.
The patient should be advised that when any of the above symptoms oc-
cur, a serious condition such as infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to seek immediate professional identiﬁ  cation of the problem and prompt treatment to avoid serious eye damage.
CR-6420, v1.0
Page 83 of 160JJVC CONFIDENTIAL
GENERAL FITTING GUIDELINES
A. Patient Selection
Patients selected to wear these lenses should be chosen based on: 
• Motivation to wear lenses 
• Ability to follow instructions regarding lens wear care
• General health 
• Ability to adequately handle and care for the lenses 
• Ability to understand the risk and beneﬁ  ts of lens wear
Patients who do not meet the above criteria should not be provided with 
contact lenses. 
B. Pre-ﬁ  tting Examination
Initial evaluation of the patient should begin with a thorough case history 
to determine if there are any contraindications to contact lens wear. During 
the case history, the patient’s visual needs and expectations should be 
determined as well as an assessment of their overall ocular, physical, and 
mental health. 
Preceding the initial selection of trial contact lenses, a comprehensive 
ocular evaluation should be performed that includes, but is not limited to, 
the measurement of distance and near visual acuity, distance and near 
refractive prescription (including determining the preferred reading distance 
for presbyopes), keratometry, and biomicroscopic evaluation. 
Based on this evaluation, if it is determined that the patient is eligible to 
wear these lenses, the Eye Care Professional should proceed to the lens 
ﬁ  tting instructions as outlined below. 
C. Initial Power Determination
A spectacle refraction should be performed to establish the patient’s 
baseline refractive status and to guide in the selection of the appropriate 
lens power. Remember to compensate for vertex distance if the refraction 
is greater than ±4.00D.
D. Base Curve Selection (Trial Lens Fitting)
The following trial lenses should be selected for patients regardless of kera-
tometry readings. However, corneal curvature measurements should be 
performed to establish the patient’s baseline ocular status. CR-6420, v1.0  
Page 84 of 160JJVC CONFIDENTIAL
• ACUVUE OASYS® 1-Day: 8.5 mm/14.3 mm
• ACUVUE OASYS® 1-Day for ASTIGMATISM: 8.5 mm/14.3 mm
The trial lens should be placed on each of the patient's eyes and evaluated 
after the patient has adjusted to the lenses.  
1. Criteria of a Properly Fit Lens 
A properly ﬁ  t lens will center and completely cover the cornea (i.e., no limbal exposure), have sufﬁ  cient movement to provide tear exchange under the contact lens with the blink, and be comfortable. The lens should move freely when manipulated digitally with the lower lid, and then return to its properly centered position when released.
2. Criteria of a Flat Fitting Lens 
A ﬂ  at ﬁ  tting lens may exhibit one or more of the following characteris-tics: decentration, incomplete corneal coverage (i.e., limbal exposure), excessive movement with the blink, and/or edge standoff. If the lens is judged to be ﬂ  at ﬁ  tting, it should not be dispensed to the patient.
3. Criteria of a Steep Fitting Lens 
A steep ﬁ  tting lens may exhibit one or more of the following charac-teristics: insufﬁ  cient movement with the blink, conjunctival indentation, and resistance when pushing the lens up digitally with the lower lid. If the lens is judged to be steep ﬁ  tting, it should not be dispensed to the patient.
If the initial trial base curve is judged to be ﬂ  at or steep ﬁ  tting, the alternate base curve, if available, should be trial ﬁ  t and evaluated after the patient has adjusted to the lens. The lens should move freely when manipulated digitally with the lower lid, and then return to a properly centered position when released. If resistance is encountered when pushing the lens up, the lens is ﬁ  tting tightly and should not be dispensed to the patient.
E. Final Lens Power (Spherical)
A spherical over-refraction should be performed to determine the ﬁ  nal lens power after the lens ﬁ  t is judged acceptable. The spherical over-refraction should be combined with the trial lens power to determine the ﬁ  nal lens prescription. The patient should e good visual acuity with the correct lens power unless there is excessive residual astigmatism.
CR-6420, v1.0 JJVC CONFIDENTIAL
Example 1
Diagnostic lens: -2.00DSpherical over-refraction: -0.25D
Final lens power: -2.25D
Example 2
Diagnostic lens: -2.00DSpherical over-refraction: +0.25D
Final lens power: -1.75D
If vision is acceptable, perform a slit lamp examination to assess adequate 
ﬁ  t (centration and movement). If the ﬁ  t is acceptable, dispense the lenses and instruct the patient to return in one week for reassessment (see dispensing and follow up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
TORIC FITTING GUIDELINES
Although most aspects of the ﬁ  tting procedure are identical for all types 
of soft contact lenses, including toric lenses, there are some additional steps and/or rules to follow to assure the proper ﬁ  t of toric lenses.
The only new steps you must follow in prescribing ACUVUE
 OASYS® 
1-Day for ASTIGMATISM are that you must determine the stability, 
repeatability, and drift angle of the lens axis so that you can prescribe the correct lens axis for the patient.
A. How to Determine Lens Cylinder and Axis Orientation 
1. Locate the Orientation Marks
To help determine the proper orientation of the toric lens, you’ll 
ﬁ  nd two primary marks approximately 1 mm from the lens edge representing the vertical position on opposite ends of the lens at 6 and 12 o’clock (Fig. 1). Because of the lens’ ballasting system, either mark can represent the vertical position – there is no “top” and “bottom” as in a prism-ballasted lens. You don’t need to view both marks to assess orientation; simply look for the 6 o’clock mark as you would with llasted lens.
CR-6420, v1.0
Page 86 of 160JJVC CONFIDENTIAL
Figure 1
You’ll need a slit lamp biomicroscope with a 1 to 2 mm 
parallelepiped beam to highlight the marks when the lens is ﬁ  tted to the eye. There are a number of techniques you can use to improve the visibility of the 6 o’clock mark. Using a parallelepiped beam and medium magniﬁ  cation (10x or 15x), slowly pan down the lens, looking just below the direct illumination at the retroilluminated area. Backlighting the mark this way should make it more visible. Sometimes manipulating the lower lid may be necessary to uncover the mark.
2. Observe Lens Rotation and Stability
Observe the position and stability of the “bottom” mark. It usually stabilizes at the 6 o’clock position. If it does, calculation of the lens power will be straightforward. The 6 o’clock position is not a “must”; however, the absolute requirement is that the axis position be stable and repeatable.
The mark may stabilize somewhat left or right (drift) of the vertical 
meridian and still enable you to ﬁ  t a toric lens for that eye, as long as the lens always returns to the same “drift axis” position after settling. The deviation can be compensated for in the ﬁ  nal prescription. Your objective is to ensure that whatever position the initial lens assumes near 6 o’clock, this position must be stable and repeatable. With full eye movement or heavy blink, you may see the marks swing away, but they must return quickly to the original stable position. If the lens does not return quickly, you may need to select a different lens.
3. Assessing Rotation
Imagine the eye as a clock dial and every hour represents a 30° interval. If the orientation mark of the initial lens stabilizes somewhat left or right of the vertical position, the ﬁ  nal lens will orient on the eye with the same deviation. You can use an axis reticule in the slit lamp or use a line-scribed lens in a spectacle trial frame to measure or estimate the “drift angle” of the cylinder axis.
To compensate for this “drift”, measure or estimate the “drift”, then 
add or subtract it from the refractive axis to determine the correct cylinder axis. Use the LARS (Left Add, Right Subtract) method to determine which direction to compensate.
CR-6420, v1.0
Page 87 of 160JJVC CONFIDENTIAL
B. Final Lens Power 
When the diagnostic lens has its axis aligned in the same meridian 
as the patient’s refractive axis, a spherocylindrical over-refraction may be performed and visual acuity determined. However, in the case of crossed axes, such as when the diagnostic lens axis is different from the spectacle cylinder axis, it is not advisable to perform a full spherocylindrical over-refraction because of the difﬁ  culty in computing the resultant power. A spherical over-refraction without cylinder refraction may be performed. 
If the required cylinder correction falls between two available cylinder 
powers, it is recommended to prescribe the lower cylinder power lens. See below for instructions on how to determine the ﬁ  nal lens power.
1. For the Sphere
If sphere alone or combined sphere and cylinder Rx > ±4.00D, 
compensate for vertex distance. If sphere alone or combined sphere and cylinder Rx ≤ ±4.00D, vertex compensation is not necessary.
2. For the Cylinder
Adjust the axis by the drift angle using the LARS method. Choose a cylinder that is ≤ 0.50D from the refractive cylinder.
3. Case Examples
Example 1
Manifest (spectacle) refraction:
O.D. -2.50D / -1.25D x 180° 20/20O.S. -2.00D / -1.00D x 180° 20/20
Choose a diagnostic lens for each eye with axis 180°. Place 
the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient’s initial response to the lens. If the lens has not yet stabilized, recheck until stable.
Check the orientation of the axis mark. If the bottom axis mark 
is in the 6 o’clock position on both eyes, choose the appropriate cylinder as listed previously. If the lens has not yet stabilized, recheck until stable.
Here is the Rx Prescribed:
O.D. -2.50D / -1.25D x 180°O.S. -2.00D / -0.75D x 180°
CR-6420, v1.0
Page 88 of 160JJVC CONFIDENTIAL
Example 2
Manifest (spectacle) refraction:O.D. -3.00D / -1.00D x 90° 20/20O.S. -4.75D / -2.00D x 90° 20/20
Choose diagnostic lenses of -3.00D / -0.75D x 90° for the right 
eye and -4.50D / -1.75D x 90° for the left eye, the nearest lenses available to the spherical power, cylinder power, and axis needed. For the left eye, since the manifest refraction called for -4.75D, compensating for vertex distance the sphere is reduced by 0.25D to -4.50D. The cylinder power will be -1.75D. Place the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient's initial response to the lens. If the lens has not yet stabilized, recheck until stable. 
Right Eye
The orientation mark on the right lens rotates left from the 6 
o’clock position by 10° and remains stable in this position. Compensation for this rotation should be done as follows: 
Compensate the 10° axis drift by adding it to the manifest 
refraction axis.
Here is the Rx Prescribed:
O.D. -3.00D / -0.75D x 100°
Left Eye
The orientation mark on the left lens rotates right from the 6 
o’clock position by 10° and remains stable in this position. 
Compensate for the 10° axis drift by subtracting it from the 
manifest refraction axis. 
Here is the Rx Prescribed: 
O.S. -4.50D / -1.75D x 80°
If vision is acceptable, perform a slit lamp examination to assess 
adequate ﬁ  t (centration and movement). If ﬁ  t is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see dispensing and follow-up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
CR-6420, v1.0
Page 89 of 160JJVC CONFIDENTIAL
MONOVISION FITTING GUIDELINES
A. Patient Selection
1. Monovision Needs Assessment
For a good prognosis, the patient should have adequately 
corrected distance and near visual acuity in each eye. The amblyopic patient or the patient with signiﬁ  cant astigmatism (greater than 1.00D) in one eye may not be a good candidate for monovision correction with these lenses.
Occupational and environmental visual demands should be 
considered. If the patient requires critical vision (visual acuity and stereopsis), it should be determined by trial whether this patient can function adequately with monovision correction. Monovision contact lens wear may not be optimal for activities such as:
• visually demanding situations such as operating potentially 
dangerous machinery or performing other potentially hazardous 
activities; and
• driving automobiles (e.g., driving at night). Patients who cannot 
meet state driver's licensing requirements with monovision correction should be advised to not drive with this correction, OR may require that additional over-correction be prescribed.
2. Patient Education
All patients do not function equally well with monovision correc-tion. Patients may not perform as well for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, progressives). Each patient should understand that monovision, as well as other presbyopic alternatives, can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. Therefore, caution should be exercised when the patient is wearing the correction for the ﬁ  rst time until they are familiar with the vision provided in visually chal-lenging environments (e.g., reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). During the ﬁ  tting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision and straight ahead and upward gaze that monovision contact lenses provide.
CR-6420, v1.0
Page 90 of 160JJVC CONFIDENTIAL
B. Eye Selection
1. Ocular Preference Determination Methods
Generally, the non-dominant eye is corrected for near vision. The 
following two methods for eye dominance can be used.
Method 1:  Determine which eye is the “sighting eye.” Have the 
patient point to an object at the far end of the room. 
Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
Method 2:  Determine which eye will accept the added power with 
the least reduction in vision. Place a hand-held trial lens equal to the spectacle near ADD in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.
2. Other Eye Selection Methods
Other methods include the "Refractive Error Method" and the "Visual Demands Method."
Refractive Error MethodFor anisometropic correction, it is generally best to ﬁ  t the more 
hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.
Visual Demands Method
Consider the patient’s occupation during the eye selection process 
to determine the critical vision requirements. If a patient’s gaze for near tasks is usually in one direction, correct the eye on that side for near.
Example: A secretary who places copy to the left side of the desk 
will function best with the near lens on the left eye.
C. Special Fitting Characteristics
1. Unilateral Vision Correction
There are circumstances where only one contact lens is required. As an example, an ent would only require a near 
lens, whereas a bilateral myope would require corrective lenses on 
CR-6420, v1.0
Page 91 of 160JJVC CONFIDENTIAL
both eyes.
Examples: A presbyopic emmetropic patient who requires a +1.75D ADD 
would have a +1.75D lens on the near eye and the other eye left without correction. 
A presbyopic patient requiring a +1.50D ADD who is -2.50D 
myopic in the right eye and -1.50D myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
2. Near ADD Determination
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient’s habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.
3. Trial Lens Fitting
A trial ﬁ  tting is performed in the ofﬁ  ce to allow the patient to experience monovision correction. Lenses are ﬁ  t according to the GENERAL FITTING GUIDELINES for base curve selection described in this Package Insert.
Case history and standard clinical evaluation procedure should 
be used to determine the prognosis. Determine the distance correction and the near correction. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.
Allow the lenses to settle for about 20 minutes with the correct 
power lenses in place. Walk across the room and have the patient look at you. Assess the patient’s reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or ﬁ  ngernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tests are completed should the patient be asked to read print. Evaluate the patient’s reaction to large print (e.g., typewritten copy) at ﬁ  rst and then graduate to newsprint and ﬁ  nally smaller type sizes.
After the patient’s er the above conditions 
is completed, tests of visual a and reading ability under 
CR-6420, v1.0
Page 92 of 160JJVC CONFIDENTIAL
conditions of moderately dim illumination should be attempted.
An initial unfavorable response in the ofﬁ  ce, while indicative of 
a guarded prognosis, should not immediately rule out a more extensive trial under the usual conditions in which a patient functions.
4. Adaptation
Visually demanding situations should be avoided during the initial wearing period. A patient may at ﬁ  rst experience some mild blurred vision, dizziness, headaches, and a feeling of slight imbalance. You should explain the adaptational symptoms to the patient. These symptoms may last for a brief minute or for several weeks. The longer these symptoms persist, the poorer the prognosis for successful adaptation.
To help in the adaptation process, the patient can be advised to 
ﬁ  rst use the lenses in a comfortable familiar environment such as in the home.
Some patients feel that automobile driving performance may not 
be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor vehicle, it may be recommended that the patient be a passenger ﬁ  rst to make sure that their vision is satisfactory for operating an automobile. During the ﬁ  rst several weeks of wear (when adaptation is occurring), it may be advisable for the patient to only drive during optimal driving conditions. After adaptation and success with these activities, the patient should be able to drive under other conditions with caution.
D. Other Suggestions
The success of the monovision technique may be further improved by having the patient follow the suggestions below:
• Have a third contact lens (distance power) to use when critical 
distance viewing is needed.
• Have a third contact lens (near power) to use when critical near 
viewing is needed.
• Having supplemental spectacles to wear over the monovision 
contact lenses for speciﬁ  c visual tasks may improve the success of monovision correction. This is particularly applicable for those patients who cannot meet state driver's licensing requirements with monovision correction.
• Make use of proper when carrying out visual tasks.
CR-6420, v1.0
0JJVC CONFIDENTIAL
Monovision ﬁ  tting success can be improved by the following 
suggestions:
• Reverse the distance and near eyes if a patient is having trouble 
adapting.
• Reﬁ  ne the lens powers if there is trouble with adaptation. 
Accurate lens power is critical for presbyopic patients.
• Emphasize the beneﬁ  ts of clear near vision and straight ahead 
and upward gaze with monovision.
The decision to ﬁ  t a patient with monovision correction is most appropriately left to the Eye Care Professional in conjunction with the patient after carefully considering the patient’s needs.
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
PATIENT MANAGEMENT
Dispensing Visit
Each sterile lens is supplied in a foil-sealed plastic package containing 
buffered saline solution with methyl ether cellulose. To remove the lens from the container, peel back the foil seal, place a ﬁ  nger on the lens, and slide the lens up the side of the bowl of the lens package until it is free of the container.
• Evaluate the physical ﬁ  t and visual acuity of the lens on each eye.
• Teach the patient how to apply and remove his or her lenses.
• Explain daily disposable lens wear and schedule a follow-up examination.
• Provide the patient with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT HE 
OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT SCHEDULES.
Follow-Up Examinations
Follow-up care (necessary to ensure continued successful contact lens wear) should include routine periodic progress examinations, management of speciﬁ  c problems, if any, and a h the patient of the wear schedule, daily disposable modality, and proper lens handling procedures. 
CR-6420, v1.0 JJVC CONFIDENTIAL
Recommended Follow-up Examination Schedule (complications 
and speciﬁ  c problems should be managed on an individual patient 
basis):
1. One week from the initial lens dispensing to patient
2. One month post-dispensing
3. Every three to six months thereafter 
NOTE: Preferably, at the follow-up visits, lenses should be worn for at least 
six hours.
Recommended Procedures for Follow-up Visits:
1. Solicit and record patient’s symptoms, if any.
2. Measure visual acuity monocularly and binocularly at distance and 
near with the contact lenses.
3. Perform an over-refraction at distance and near to check for residual 
refractive error.
4. With the biomicroscope, judge the lens ﬁ  tting characteristics (as 
described in the GENERAL FITTING GUIDELINES) and evaluate 
the lens surface for deposits and damage.
5. Following lens removal, examine the cornea and conjunctiva with 
the biomicroscope and ﬂ  uorescein (unless contraindicated).
• The presence of vertical corneal striae in the posterior central 
cornea and/or corneal neovascularization is indicative of 
excessive corneal edema.
• The presence of corneal staining and/or limbal-conjunctival 
hyperemia can be indicative of an unclean lens, a reaction to solution preservatives, excessive lens wear and/or a poorly ﬁ  tting lens.
• Papillary conjunctival changes may be indicative of an unclean 
and/or damaged lens.
6. Periodically perform keratometry and spectacle refractions. The 
values should be recorded and compared to the baseline meas-
urements.
If any observations are abnormal, use professional judgment to 
alleviate the problem and restore the eye to optimal conditions. If CR-6420, v1.0  
Page 95 of 160JJVC CONFIDENTIAL
the criteria for successful ﬁ  t are not satisﬁ  ed during any follow-up 
examinations, repeat the patient’s trial ﬁ  tting procedure and reﬁ  t 
the patient.
WEARING SCHEDULE
The wearing schedule should be determined by the Eye Care Professional.   
Regular checkups, as determined by the Eye Care Professional, are also extremely important.
Patients tend to overwear the lenses initially. The Eye Care Professional 
should emphasize the importance of adhering to the initial maximum wear-ing schedule.  Maximum wearing time should be determined by the Eye Care Professional based upon the patient’s physiological eye condition, because individual response to contact lenses varies.
The maximum suggested wearing time for these lenses is:
Day Hours
1 6-8
2 8-10
3 10-12
4 12-14
5 and after all waking hours
REPLACEMENT SCHEDULE
These lenses are indicated for daily disposable wear and should be 
discarded upon removal.
LENS CARE DIRECTIONS
When lenses are prescribed for daily disposable wear, the Eye Care Professional should provide the patient with appropriate and adequate warnings and instructions for daily disposable lens wear at the time they are dispensed. 
CR-6420, v1.0
Page 96 of 160JJVC CONFIDENTIAL
The Eye Care Professional should review with patients that no cleaning 
or disinfection is needed with daily disposable lenses. Patients should always dispose of lenses when they are removed and have spare lenses or spectacles available.
Basic Instructions
• Always wash, rinse, and dry hands before handling contact lenses.
• Do not use saliva or anything other than the recommended solutions 
for lubricating or rewetting lenses. Do not put lenses in the mouth.
• Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to wet (lubricate) lenses while they are being worn to make them more comfortable. 
Care for a Sticking (Non-Moving) Lens
If the lens sticks (stops moving), the patient should be instructed to apply 
a few drops of the recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, the patient should immediately consult the Eye Care Professional.
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT THE EYE CARE PROFESSIONAL OR VISIT A HOSPITAL EMERGENCY ROOM WITHOUT DELAY. 
HOW SUPPLIED
Each UV-blocking sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with methyl ether cellulose. The plastic package is marked with the following: 
• ACUVUE OASYS
® 1-Day: base curve, power, diameter, lot number, 
and expiration date
• ACUVUE OASYS® 1-Day MATISM: base curve, power, 
diameter, cylinder, axis, lot and expiration dateCR-6420, v1.0
Page 97 of 160JJVC CONFIDENTIAL
REPORTING OF ADVERSE REACTIONS
All serious adverse experiences and adverse reactions observed in 
patients wearing these lenses or experienced with these lenses should be reported to:
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway
Jacksonville, FL 32256
USA
Tel: 1-800-843-2020
www.acuvue.com
CR-6420, v1.0
Page 98 of 160JJVC CONFIDENTIAL
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway
Jacksonville, FL 32256
USA
Tel: 1-800-843-2020
www.acuvue.com
©Johnson & Johnson Vision Care Companies 2016
In Canada: Johnson & Johnson Vision Care, division of Johnson & Johnson, Inc. 
In USA: Johnson & Johnson Vision Care, Inc.
Printed in USA.
Revision date: 09/16
Revision number: AO-03-16-13
ACUVUE OASYS® and e ™ are Trademarks of 
the Johnson & Johnson Vision Care Companies20401080
CR-6420, v1.0
Page 99 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX D:   
x LENS FITTING CHARACTERISTICS
x SUBJECT REPORTED OCULAR SYMPTOMS
x  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS 
x  BIOMICROSCOPY SCALE 
x DISTANCE AND NEAR VISUAL ACUITY EVALUATION 
x TORIC FIT EVALUATION
x ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE
x  PATIENT REPORTED OUTCOMES
x  LENS INSERTION AND REMOVAL
x VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING
CR-6420, v1.0
Page 100 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 LENS FITTING CHARACTERISTICS   
CR-6420, v1.0
Page 101 of 160JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  Work Instructions
Document Number :  Revi sion Number:  5
Page 1of 5CR-6420, v1.0
Page 102 of 160JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  Work Instructions
Document Number :  Revi sion Number:  5
Page 2of 5              
       
CR-6420, v1.0
Page 103 of 160JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  Work Instructions
Document Number :  Revi sion Number:  5
Page 3of 5CR-6420, v1.0
Page 104 of 160JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  Work Instructions
Document Number :  Revi sion Number:  5
Page 4of 5CR-6420, v1.0
Page 105 of 160JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  Work Instructions
Document Number :  Revi sion Number:  5
Page 5of 5CR-6420, v1.0
Page 106 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SUBJECT REPORTED OCULAR SYMPTOMS  
 
CR-6420, v1.0
Page 107 of 160JJVC CONFIDENTIAL
Title:                         Subject Reported Ocular Symptoms/Problems
Document Type:  Work Instructions
Document Number :  Revi sion Number:  3
Page 1of 1  
  
            
CR-6420, v1.0
Page 108 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
CR-6420, v1.0
Page 109 of 160JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  Wor kInstructions
Document Number :  Revi sion Number:  5
Page 1of 5  
CR-6420, v1.0
Page 110 of 160JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  Wor kInstructions
Document Number :  Revi sion Number:  5
Page 2of 5CR-6420, v1.0
Page 111 of 160JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  Wor kInstructions
Document Number :  Revi sion Number:  5
Page 3of 5CR-6420, v1.0
Page 112 of 160JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  Wor kInstructions
Document Number :  Revi sion Number:  5
Page 4of 5CR-6420, v1.0
Page 113 of 160JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  Wor kInstructions
Document Number :  Revi sion Number:  5
Page 5of 5CR-6420, v1.0
Page 114 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
BIOMICROSCOPY SCALE  
 
CR-6420, v1.0
Page 115 of 160JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type: Work Instruction
Document Number: Revision Number:  9
CR-6420, v1.0
Page 116 of 160JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type: Work Instruction
Document Number: Revision Number:  9
CR-6420, v1.0
Page 117 of 160JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type: Work Instruction
Document Number: Revision Number:  9
CR-6420, v1.0
Page 118 of 160JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type: Work Instruction
Document Number: Revision Number:  9
CR-6420, v1.0
Page 119 of 160JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type: Work Instruction
Document Number: Revision Number:  9
  
CR-6420, v1.0
Page 120 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
CR-6420, v1.0
Page 121 of 160JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 1of 4  
CR-6420, v1.0
Page 122 of 160JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  Wor k Instructions
Document Number : Revi sion Number:  4
Page 2of 4CR-6420, v1.0
Page 123 of 160JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  Wor k Instructions
Document Number : Revi sion Number:  4
Page 3of 4CR-6420, v1.0
Page 124 of 160JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 4of 4CR-6420, v1.0
Page 125 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TORIC FIT EVALUATION  
CR-6420, v1.0
Page 126 of 160JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  Work Instructions
Document Number :  Revi sion Number:  6
Page 1of 4.
CR-6420, v1.0
Page 127 of 160JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  Work Instructions
Document Number : Revi sion Number:  6
Page 2of 4CR-6420, v1.0
Page 128 of 160JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  Work Instructions
Document Number :  Revi sion Number:  6
Page 3of 4 
CR-6420, v1.0
Page 129 of 160JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  Work Instructions
Document Number :  Revi sion Number:  6
Page 4of 4CR-6420, v1.0
Page 130 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE  
 
CR-6420, v1.0
Page 131 of 160JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type: Clinical Test Procedure 
Document Number:   Revision Number: 4 
 
Page 1 of 3 
   
CR-6420, v1.0
Page 132 of 160JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type: Clinical Test Procedure 
Document Number:   Revision Number: 4 
 
Page 2 of 3 
  
CR-6420, v1.0
Page 133 of 160JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type: Clinical Test Procedure 
Document Number:   Revision Number: 4 
 
Page 3 of 3 
 CR-6420, v1.0
Page 134 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PATIENT REPORTED OUTCOMES  
 
CR-6420, v1.0
Page 135 of 160JJVC CONFIDENTIAL
Title: Patient Reported Outcomes
Document Type: Procedure
Document Number: Revision Number: 2
Page 1of 1                      
CR-6420, v1.0
Page 136 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
LENS INSERTION AND REMOVAL  
 
CR-6420, v1.0
Page 137 of 160JJVC CONFIDENTIAL
Title:   Lens Insertion and Removal
Document Type: Work Instructions
Document Number : Revi sion Number:  2
Page 1 of 2CR-6420, v1.0
Page 138 of 160JJVC CONFIDENTIAL
Title:   Lens Insertion and Removal
Document Type: Work Instructions
Document Number : Revi sion Number:  2
Page 2 of 2
CR-6420, v1.0
Page 139 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
VISUAL ACUITY CHART LUMINANC E AND ROOM ILLUMINATION 
TESTING  
CR-6420, v1.0
Page 140 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 1of 8CR-6420, v1.0
Page 141 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 2of 8CR-6420, v1.0
Page 142 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 3of 8CR-6420, v1.0
Page 143 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 4of 8CR-6420, v1.0
Page 144 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 5of 8CR-6420, v1.0
Page 145 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number : Revi sion Number:  4
Page 6of 8CR-6420, v1.0
Page 146 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 7of 8CR-6420, v1.0
Page 147 of 160JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  Wor k Instructions
Document Number :  Revi sion Number:  4
Page 8of 8CR-6420, v1.0
Page 148 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX E: GUIDELINES FOR COVID -19 RISK MITIGATION  
CR-6420, v1.0
Page 149 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
1.0 PURPOSE
The purpose of this doc ument is to provide guidelines for the re -opening or initiation of clinical study sites 
participating in Johnson &Johnson Vision Care, Inc. ( JJVCI )clinical studies dur ing the COVID -19
pandemic.
2.0 SCOPE
This document provides guidelines for Johnson &Johnson Vision Care ( JJVCI )to address the potential risks 
from COVID -19 to study subjects ,investigators, study site staff, and monitors at study sites.The guidance 
provided in this document is in effect from the date of approval through th e date of retirement of this Work 
Instruction. At a minimum ,this Work Instruction will be  reviewed and updated on a quarterly basis, a s
appropriate.
NOTE:  Re-opening of s ites outside of the US will be evaluated on a country by country basis subject 
to local health authority guidance.
3.0 DEFINITIONS
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, Flor ida. Its goal is to maintain and enhance excellence in optometric 
practice, by both promoting research and the di ssemination of knowledge. The AAO holds an annual 
meeting, publishes a monthly scientific journal, give s credentials to optometrists  through the fellowship 
process and publishes position statements.
American Optometric Association ( AOA ):The American Optom etric Association, founded in 1898, is 
the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 
Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take 
a leading role in patient care with respect to eye and vision care, as well as general health and well -being. 
As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, 
diagnose, treat and manage ocular disorders, diseas es and injuries and sys temic diseases that manifes t in the 
eye. The American Optometric Asso ciation is a federation of state, stud ent, and armed forces optometric 
associations. Through these affiliations, the AOA serves me mbers consisting of optometrists, students of 
optometry, paraoptometric assistants a nd technicians. The AOA and its aff iliates work to provide the public 
with quality vision and eye care.
Center sfor Disease Control and Prevention (CDC ):The Centers for Disease Control and Prevention is a 
national public health institute in the United States. It is a United States federal agency, under the 
Department of Health and Human Services, and is headquartered in Atlanta, Georgia.
COVID -19: Current outbreak of respiratory  disease caused by a novel coronavirus. The virus has been 
named “S ARS -CoV -2” and the disease it causes has been  named “Coronavirus Disease 2019” (COVID -
19).
Clinical Study: Voluntary research studies cond ucted in people and designed to answer specific questions 
about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing 
treatments. May also be called clinical trials, studies, research, trials, or protocols.
Clinical Study Site: Location where a clinical study is  conducted, such as a doctor’s office, university, or 
laboratory. Clin ical studies are conducted by Investigators who are individual(s) responsible for the 
conduct of the clinical study at a study site. If a stud y is conducted by a team of individuals, the 
Investigator is the responsible leader  of the team and may be called the Principal Investigator.
Clinical Operations Manager (COM) :The Johnson & Johnson Vision Care ( JJVC I) individual 
responsible for the overall ma nagement of a clinical trial.
CR-6420, v1.0
Page 150 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
Monitor: Anindividual designated to oversee the progress of a clinical study and ensure that it is 
conducted, recorded, and reported in accordance with  the protocol, Standard Operating Procedures (SOPs), 
Good Clinical Practice (GCP), and ap plicable regulatory requirements.
Medical Safety Officer (MSO) :Physician who has prim ary accountability in their product portfolio for 
product health and safety, and who serves as an independent medical voice for patient safety.
Safety Management Team (SMT) :A cross -functional, collaborative team responsible for review, 
assessment and eva luation of medical safety data arising from any source throughout the product life cycle.
4.0 GUIDANCE FOR STUDY DOCUMENTS
In alignment with recent health authorit yguidance, JJVCI is providing recommendations for study -related 
management in the event of disruption to the conduct of the clinical study. This guidance does not supersede 
any local or government requirements or the clinical judgement of  the investigator to protect the health ,safety
and well -being of particip ants and site staff. If, at an y time, a participant’s safety is considered to be at risk, 
study intervention will be discontinued, and study follow -up will be conducted as outlined in the protocol.  
During the COVID -19 pandemic, the additional risks liste d below need to be considered for study participants 
and study personnel :
Additional Risks Related to the COVID -19 Pandemic:
xThe p ossible transmission of the Coronavi rusinfection and consequent complications, beyond the 
risk of adverse events due to the investigational device and/or procedures .
xThe risk may be higher in an op tometric clinical study because of the close contact the subject will 
have with health care professionals during the proce dures and assessments (since the investigator
must make the measurements close to the subject’s face) and, in addition the need for multiple 
follow -up visits/exams which may expose the subject to other patients and/or healthcare 
professionals who might be transmitting the virus ,even if they do not have symptoms.
xPotential disruptions to the study may be nece ssary due to current or future pandemic -related 
emergency restrictions, which may lead to delays in scheduled follow -up visits.
xSubjects experienc ingan adverse event related to contact lens wear may receive delayed treatment 
due to COVID -19restrictions. In this event, a ll assessments that can be conducted virtually will be 
completed by the investigator to determine the best course of treatment for the subject, including
anunscheduled visit, up to discontinuation from the study , as appropriate .
Ifastudy subject is found to  have contracted COVID -19during participation in astudy, he/she will be 
discontinued from the study and follo wed until COVID -19Adverse Event (AE) resolution.
To help minimize the above potential risks, JJVCI recommend reviewing/complying with local, state, 
and governmental guidance for COVID -19 risks. 
JJVC Iwill provide the following study specific documents wi th language pertaining to COVID -19 risks:
4.1.1 Informed Consent :
Will include information concerning the study -associated risks relate d to the COVID -19 pandemic 
in bold font and/or boxed on the first page of the I nformed Consent document:
CR-6420, v1.0
Page 151 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS ) PANDEMIC
It is important to note that this  study will be conducted, at leas t in part, during the COVID -19 pandemic. As such, 
additional risks associated with  the infection with COVID -19 exist for you. Thi s is particularly important for this 
study due, in part, to the closeness of the doctor during the study examinations. 
The potential effects of the dise ase are not fully known, at th is time, and may include long -term serious health 
consequences. In sever e cases, this may result in hospitalization and/or death. Based on current knowledge from the 
Center sfor Disease Control and Prevention (CDC), those at high -risk for severe illness from COVID -19 include 
older adults and people w ith underlying medical cond itions. 
During this study, all appropriate measur es will be taken to minimize risks in cluding the use of personal protective 
equipment such as masks and glov es, as well as proper sanitization. This is in conformance to guidance from the 
CDC, local healt h departments, and the state and county in which the study doctor’s office  is located. However, 
these measures may not completely eliminate th e risks associated with contracting COVID -19. 
If you are found to have contracted COVID -19 or feel ill with flu -like symptoms during pa rticipation in the study, 
you will not be permitted to continue in -office study follow -up visits ,but you will receive instructions and your 
condition will be monitored by the doctor and/or study staff.
4.1.2 COVID -19 Risk Control Check list:
Will include COVID -19 risk control methods that are required by a site to conduct JJVCI clinical studies. 
The risk controls are co nsistent with CDC, AOA, AAO Guidance. The Principle Investigator will review/sign 
the study specific ch ecklist prior to the Site Initiation Meeting.
Study Number
Site Number
Principal Investigator (PI) Name
The following COVID -19 risk control methods are required to conduct Johnson & Johnson Vison Care clinical 
studies. Please review the following requirements and Initial each requirement.
PI Initials General Site Safety Planning Measures
Signage within site descri bing Risk Control methods
Social Distancing practices throughout site (waiting rooms, lobby, exam rooms, etc.)
Non-contact thermometer available to assess temperatures of staff and patients
Training on patient flow and p hysical distancing in waiting room
Establish longer time frame between patient appo intments to reduce persons in the site
Staff should receive job-specific training on PP E and demonstrate competen cy with selection and 
proper use of PPE and we ar at all times during interactions with subjects (e.g., putting on and 
removing without self-contamination)
PI Initials Site Staff Daily Safety Measures
As part of routine practice, site staff should regular ly monitor themselves for fever and symptoms 
of COVID-19, including temperature checks 
Any staff member (including I nvestigators) showing signs of be ing sick or testing positive for 
COVID -19 should not be permitted to work and the Sponsor shall be informed
NOTE: Inform JJVC in 24 hours of any significant impact to the study.
Ensure that all staff wear a mask
Gloves should be required when working directly  with patients and changed between each patient
CR-6420, v1.0
Page 152 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
Have staff thoroughly wash hands for at least 20 seconds or use an alcohol-based hand sanitizer 
when they arrive, before and after each patien t, before eating and after using the bathroom.
Cleaning and disinfection procedures for exam rooms and instruments or equipment between 
patients with gloves.
Cleaning and disinfection procedures for commonl y touched surfaces (doors, chairs, computers, 
phones, etc.) with gloves.
PI Initials Before a Patient or Study Visit:
Patients should be asked prior to entering the s ite about fever and respir atory illness and whether 
they or a family member have had contact with another person with confirmed COVID -19 in the 
past 14 days. Patients exhibiting signs of being s ick should be rescheduled when their symptoms 
resolve.
Instruct patients that companions should remain outside of  the facility and not accompany the 
patient into the facility unless they  are a parent/guardian of the patient or if they are a true 
caregiver and need to assist the patient
Request the patient to  call or text the office upon arrival so entrance to and movement through 
facility can be coordi nated by site staff
PI Initials Patients Entering the site:
Temperature checks utilizing a non-contact thermo meter for all patients and companions entering 
the site.
All patients and companions must wear cloth  or disposable mask at all times in the site
Maintain social distancing. Waiting rooms or lobbies should be as empty as possible. Advise 
seated patients to remain at le ast 6 feet from one another. 
Communal objects in (e.g. toys, re ading materials, etc.) should be removed or cleaned regularly.
I certify that I have read and agre e to implement a ll the listed COVID -19 Risk Control Measures required for the 
conduct of Johnson & Johnson Vision Care studies. 
Principal Investigator Signature and Date
CR-6420, v1.0
Page 153 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
RESOURCE LINKS
US Resource Links 
xOSHA Training
https://www.osha.gov/SLTC/covid -19/controlprevention.html
Personal Protective Equipment ( PPE)Training
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/using -ppe.html
xI&R Training
ACUVUE®LensAssist: https://www.acuvue.com/lensassist    
xClinic Preparedness Guides
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/clinic -preparedness.html
AOA: https://aoa.uberflip.com/i/1240437 -aoa-guidance -for-re-opening -practices -covid·19/1?m4=
American Optom etric Association: https://www.aoa.org/optometry -practice -reactivation -preparedness -
guide
xln-Office Disinfection of Multi -Patient Use Diagnostic Contact Lenses
https://www.gpli.info/wp -content/uploads/2020/03/2020 -01-15-in-office -disinfecting -of-diagnostic -
lenses.pdf
OUS Resource Links 
xUpdates on local regulations in Hong Kong
https://www.coronavirus.gov.hk/eng/index.html
xResumption of optical services in England: Letter from Matt Neligan and Poonam Sharma
https://www.england.nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0601 -reopening -of-optical -
services -letter -17-june-2020.pdf
xNHS Optical Letter
https://www.england.nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0127 -optical -letter -1-april-
2020.pdf
xThe College of Opto metrists primary eye care COVID -19 guidance: Red phase
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavirus -covid -19-guidance -
for-optometrists.html
xThe College of Optometrists COV ID-19: College updates
https://www.college -optometrists.org/the -college/media -hub/news -listing/coro navirus -2019 -advice -for-
optometrists.html# CollegeGuidelines
xInfection Control Guidelines. (n .d.). Retrieved from Canadian  Association Of Optometrists: 
https://opto.ca/sites/default/fil es/resources/documents/infect ion_control_guidelines_2016.pdf
xInfection prevention an d control for COVID -19: Interim guidance for outpatient and ambulatory care 
settings. (2020, May 23 May). Retrieved from Government of Cana da: https://www.canada.ca/en/public -
health/services/diseases/2019 -novel -coronavirus -infection/guidance -documents/interim -guidance -
outpatient -ambulatory -care-settings .html
CR-6420, v1.0
Page 154 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
xInformation for Members On Coronavirus (COVID -19). (n.d.). Retrieved from Canadian As sociation Of
Optometrists: 
https://opto.ca/sites/def ault/files/resources/documents/information_for_members_on_coronavirus.pdf
xCoronavirus (COVID -19) resources for health professionals, in cluding aged care providers, pathology 
providers and he alth care managers. (2020, September 24 ). Retrieved from Australian Government 
Department of Health:
https://www.health.gov.au/res ources/collections/coronavirus -covid -19-resources -for-health -professionals -
including -aged -care-providers -pathology -providers -and-health -care-managers
 
xEnvironmental Cleaning and Disi nfection Principles for COVID -19. (n.d.). Retrieved from Australian 
Government Department of Health: 
https://www.health.gov.au/s ites/default/files/documents /2020/03/environmental -cleaning -and-disinfe ction -
principles -for-covid -19.pdf
xInfection control guidelines and advice. (n .d.). Retrieved from Optometry Australia : 
https://www.optometry.org.au/practice -professional -support/coronavirus -covid -19-what -optometrists -need -
to-know/covid -19-clinical -advice/ infection -control -guidelines -and-advice/
 
4.1.3 Protocol Compliance Investigator(s) Signature Page :
Will include a statement indicating thatthePrincipal Investigator ( PI)agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s for COVID -19 risk mitigation. 
I have read the sugges ted guidance provided by JJVCI pertaining to the COVID -19 risk mitigation,
(COVID -19 Work Instruction in the Appendix of this protocol) .I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.
4.1.4 Study Site Initiation Training Slides :
Will include suggestions to help mitigate potential transmission of COVID -19. Suggestions may 
include maintaining social distan cing in the clinical site by staggered scheduling of study p atients,
wearing proper PPEs, frequent disinfection, and installing sh ields on the slit lamp and other 
applicable equipment .
5.0 GUIDANCE FO R REMOTE SUBJECT VISITS
Potential disruptions to the study may be nece ssary due to current or future pandemic -related emergency 
restrictions .  Possible disruption of the study as a result of COVID -19 control measures may lead to delays 
in scheduled follow -up visits.
Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID -19 control 
measures or due to the subject’s concerns or fears about COVID -19risk.When appropriate , the remote 
assessment willbe conducted to the extent possible.  Discussions with the subject during remote assessments 
may include:
CR-6420, v1.0
Page 155 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
Procedure Details
Subject Reported Ocular 
SymptomsSubjects will respond to a verbal ope n-ended symptoms questionnaire 
regarding the test article when applicable and feasible. 
Change of Medical History 
(Adverse Events) and Concomitant Medications / 
Therapies ReviewRecord any adverse events or medical history changes from the 
previous study visit w ith the subject/parents.
Review the subject’s concomitant medications/therapies and record 
any changes from the previous study visit.
Wearing Time and 
ComplianceRecord the average wearing time (in cluding number of hours per day 
during weekdays and weekends, and number of days per week).
Confirm compliance with the prescribed wear schedule.
xRecord and discuss the lens wear compliance based on the 
subject’s self -report. For example, the subjects w ill be asked the 
time of the day the subject typic ally puts on the study lenses in the 
morning and takes off in the evenin g, the number of days per week 
lenses were worn, and the number of consecutive days the subject 
didn’t wear the study lenses, etc.
The discussion with the subject w ill be documented in EDC under Tele -Visit and a minor protocol deviation 
will be noted. If during the telephone consultation ,asubject states he/ shewish esto discontinue participating 
in the study, instruct the subject to stop wearing the study lenses an d schedule the subject to return to the 
clinic for a Final Evaluation at  the at earliest possible tim e. Subjects should return all unused lenses to the 
clinic at the last visit.
Changes in study visit schedules, missed visits, or participant discontinuations may lead to missing data, 
including data related to protocol -specified procedures. Case report forms should capture specific 
information regarding the ba sis of missing data, including the relationship to the COVID -19 pandemic.
6.0 STUDY CONDUCT DURING PANDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may have an impact on the conduct 
of this clinical study due to, for example, sel f-isolation/quarantine by participants and study -site personnel; 
travel restrictions/limited access to public places, including Optometry Clinics ; and changes in clinic 
procedures required to address the COVID -19 challenge.
Every effort should be made to adhere to protocol -specified assessments for study participants, including 
follow -up. However, if scheduled visits cannot be conducted in person at the study site it is suggested that 
assessments be performed to the extent possible remotely/virtually or delayed until such time that on -site 
visits can be resumed in order to continue participant monitoring in accordance with the protocol where 
possible. At each con tact, participants will be interviewed to collect sa fety data. Key effic acy endpoint 
assessments should be performed if required and as feasible.
Modifications to protocol -required assessments may be permitted via COVID -19 Appendix after consultation 
with the participant, inve stigator, and the sponsor. Missed assessments/visit s will be captured in the clinical 
trial management system for protocol deviations. Interruptions of test article wear or discontinuations of 
study interventions and withdrawal from the study should be documented with the prefix “COVID -19-
related” in the c ase report form (CRF).
CR-6420, v1.0
Page 156 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
The sponsor will continue to monitor the conduct and progress of the clinical study, and any changes will be 
communicated to the sites and to the health authorities ac cording to local guidance.
 
If a participant has tested positive for COVID -19, the investigator should co ntact the sponsor’s responsible 
medical monitor to discuss initial plan s for study intervention and follow -up. The medical monitor will 
notify the Safety Management Team of  any subject(s) that have reported “COVID -19”, “Asymptomatic 
COVID -19”, or “Suspected COVID -19” adverse events within 24 hours of the notification. 
Modifications made to the study c onduct as a result of the COVID -19 pandemic will be summarized in the 
clinical study report.  
COVID -19 scree ning procedures that may be mandate d by local healthcare systems do not need to be 
reported as an amendment to the protocol even if done during clinical study visits.
Monitoring Visits
When on -site monitoring by the sponsor is not feasible ,the sponsor’s s ite monitor will contact the study 
site to schedule remote visits. In such cases, on -site monitoring visits will resume when feasible, with
increased frequency to address th e source data verification backlog.
Even with staffing lim itations during this COVI D-19 pandemic, all routine operations related to clinical 
trials should be well -documented and archived as pa rt of standard process. When conditions permit, all 
parties involved in this clinical  trial should communicate relevant information in a timely manner so that 
all relevant parties remain  sufficiently informed.
6.1.1 Study Site Initiation:  
During the period that this Work Instruction is in effect , Site Initiation Meetings and training of 
study site staff will be conducted remotely .The JJVCI study team will conduct training via Skype, 
Zoom, Microsoft Teams or similar software as well as utilize online training materials ,as applicable.  
Study site training will be documented utilizing Site Initiation Report
per Study Site Initiation 
On-site visits may be considered when, for example, hands -on training or evaluation of site facilities 
is required. While on site, the Clinical Research Associate ( CRA )will follow all local, state, and 
governmental policies for COVID -19 Risk Mitigation, including socia l distancing, wearing of PPE, 
etc. as applicable for the lo cation of the study site.
6.1.2 Interim Monitoring Visits (if applicable) :
During the period that this Work Instruction is in eff ect, Interim Monitoring On-site v isits will be 
kept to a minimum and include only those tasks that the CRA cannot perform remotely (e.g., source 
document verification , test article reconciliation, etc.).
To ensure data integrity during the conduct of all JJVC studies, clinical study teams will follow the 
study specific Clinical Monitoring Plan
While on site, the CRA will follow all local,  state, and governmental policies for COVID -19 Risk 
Mitigation, including social distancing, wearing of PPE, etc. as applicable for the location of the 
study site.
CR-6420, v1.0
Page 157 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
6.1.3 Study Site Closure:  
During the period that this Work Instruction is in effect, the durati on of the Study Site Closure Visit 
will be lim ited to tasks that the CRA cannot pe rform remotely (e.g., source document verification, 
test article final rec onciliation and return, etc.).  
CR-6420, v1.0
Page 158 of 160JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type: Work Instruction
Document Number: Revision Number: 4
 
Attachment A: Study Site Correspondenc e
XXXX XX, 2020
Re: COVID -19 Mitigation Plan, << CR-xxxx/protocol title>>
Dear <<Princip alInvestigator>> and Study Team,
Coronavirus (COVID -19) has impacted several communities and busi ness activities over the past several months. 
While we work toward the successful  conduct of clinical studies, our commitmen t continues to be the safety of 
patients, healthcare profession als, and to our communities. 
Therefore, we would like to share th e following revisions/additions related to the above referenced Johnson & 
Johnson Vision Care company sponsored clinical trial(s) you are currently working on or considering participation 
within. 
Protocol:
xGuidelines for COVID -19 Risk Mitigation provided in the Appendix section.
Protocol Signature Page:
xWill include a statement indicating the Prin ciple Investigator agrees to conduct the study in compliance 
with all local, state, and gove rnmental guidelines for COVID -19 risk mitigation.
Informed Consent:
xWill include information concerning the study -associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent document.
COVID -19 Risk Control Checklist for Clinical Studies:
xWill include COVID -19 risk control measures that ar e required to ensure the saf ety and health of subjects, 
site staff and monitors during the pandemic.   
We want to e ncourage the need for open lines of communication about potential challenges you may foresee as the 
result of the current COVID -19 situation. Therefore, we encourage you  to regularly connect with your respective 
Johnson & Johnson clinical study team ( Clini cal Research Associate ( CRA ),Lead CRA or Study Managers).  
Thank you for your continued engageme nt, collaboration, and dedication to your study subjects during this 
challenging time. 
Please file this letter in your s ite file study correspondence. 
CR-6420, v1.0
Page 159 of 160JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL COMPLIANCE INVEST IGATOR(S) SIGNATURE PAGE  
Protocol Number and Title: CR-6420 Evaluation of ACUVUE OASYS® 1 -Day for Astigmatism 
Lenses Produced on a New Manufacturing Line
Version and Date: 1.005 November 2020
I have read and understand the protocol specified above and agree on its content.  
I agree to conduct this study according to ISO 14155 ,1GCP and ICH guidelines ,2the Declaration 
of Helsinki ,3United States (US) Code of Federal Regulations (CFR) ,4and the pertinent individual 
country laws/regulations and to comply with it s obligations, subject to ethical and safety 
considerations. The Princ ipal Investigator is respons ible for ensuring that all clinical site personnel, 
including Sub -Investigators adhere to all ICH2regulations and GCP g uidelines regarding clinical 
trials during and after study completion.
I will assure that no deviation from or changes to the protocol will take place without prior 
agreement from the Sponsor and documented approval from the Institutional Review Board (IR B),
except where necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub -Investigators adhere to 
all ICH2regulations and GCP guidelines regarding clin ical trials during and after study completion.
All clinical site personnel involved in the conduct  of this study have completed Human Subjects 
Protection Tra ining. 
I agree to ensure that all clinical site personnel involved in the conduct of this study are informed 
about their obligations in meeting the above commitments.
I shall not disclose the information contai ned in this protocol or any results obtaine d from this 
study without written authorization.
I have read the suggested guidance prov ided by JJVCI pertaining to the COVID -19 risk mitigation, 
(COVID -19 Work Instruction in the Appendix Eof this protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.
Principal 
Investigator:
Signature Date
Name and Professional Position (Printed)
Institution/Site:
Institution/Site Name
Institution/Site Address
CR-6420, v1.0
Page 160 of 160JJVC CONFIDENTIAL